YC Spring 2026 Batch: All 194 Companies, Scored

What it does. automated influencer marketing

The public-data read. Real, transactional demand (11.6k/mo, 83% transactional, KD 32) and a genuine switching complaint on r/influencermarketing. But it is a knife fight against CreatorIQ, GRIN, impact.com and Aspire, all SEO-led, and the funded 2020-22 wave never cracked the category open. Monetization is the bright spot (0.7-month payback).

What it does. product analytics for agents

The public-data read. Almost no search yet (260/mo, KD 0) because "agent analytics" is a category you would have to create, while Pendo, Amplitude, Mixpanel and PostHog own human analytics. Pain reads neutral. The unit math is the worry: $2-49/mo against $156-519 CAC is a 14-month payback before any churn.

What it does. self-healing logging

The public-data read. Decent intent (1,870/mo, 100% transactional) but you walk into Datadog, Dynatrace, New Relic and Splunk, the most concentrated, highest-CAC market in the batch ($580-1,932, CPC $58). Funded observability challengers got absorbed, not breakout. The pain quote is a vendor-comparison thread, not a fire.

What it does. memory layer for agents

The public-data read. Good intent (1,560/mo, 96% transactional, KD 20) and a clean switching signal on r/AI_Agents ("need better memory systems, not just bigger context windows"). But it is the most crowded thesis in AI infra (mem0, Zep, Letta, Cognee) and social pain reads thin (17/30).

What it does. data ops for mid-market

The public-data read. Strong demand (11.1k/mo, 94% transactional, KD 22) and a real "do we still need Python/ETL" anxiety on Quora. But "Palantir for mid-market" means fighting Databricks, Alteryx, Appian and C3, and the model's 559-month payback says the ACV assumptions are wrong.

What it does. Builds autonomous robots and an operating system for industrial work across logistics, manufacturing, and service operations.

The public-data read. Top LRS in the batch, carried entirely by the demand and economics pillars: 7,150 searches/mo at 100% transactional intent, KD 13, plus a perfect 20/20 monetization and HOT funding (Theker's $85M Series A on 2026-06-11, Darkhive $30M). But this is an atoms business, not bits, and the public-data lens flatters it badly. The competitor map reads "count 2" with no named players, which is low-confidence noise for a field that actually includes the funded peers in the dossier's own funding list; treat the FAVORABLE 21.6/24 competition score skeptically. Pain is the soft spot at CHRONIC 21/30, Medium evidence, and the quotes are abstract industry musing, not operators in budgeted pain: the top Quora thread literally asks "What are the current limitations and challenges facing the present robotics industry?" The 0.1-month payback on $58-194 CAC is implausible for a company that has to manufacture and physically deploy hardware priced "$16,000-$250,000 per robot" — the model is reading SaaS math onto a capex sale, so that payback figure should be discarded.

What it does. AI-native medical billing for independent practices, handling coding review, claim submission, denials, and patient billing.

The public-data read. This is the only PROMISING (Hot) idea in the batch and the demand quality is the reason: 370 searches/mo but 100% transactional intent and the lowest KD in the set at 12, with BURNING pain (24/30) and a clean budget-proof of 9/10 against a scraped band of $50-$6,000/mo. The standout is a genuinely on-topic, buyer-voiced pain quote from r/PrivatePracticeDocs: "I've been looking at AI agents bc no matter how much I train my clinicians to bill correctly, they still screw it up all the time," which is a practice owner with a budget describing the exact problem, not a curious bystander. The competitive set is serious incumbents (athenahealth, AdvancedMD, CureMD, Adonis) who own RCM today, so the wedge has to be "AI-native for independents" against suites that already bundle billing into the EHR. Category capital is legible and supportive of the space: Tebra ($72M, OS for independent providers), Heard ($15M, billing for therapists), and Practice Ignition ($50M, automated billing) are plausible adjacent comps, signaling real investor appetite for billing tooling aimed at small practices, though none is a pure AI-RCM twin. The sector tag reads Fintech but this is really healthcare RCM. The unscored layer is meaningful but manageable: medical billing touches HIPAA/PHI handling, payer-clearinghouse integrations, and coding-compliance liability (a miscoded claim is a real financial and audit risk), so trust and integration depth, not demand, are the moat.

What it does. AI money agent that links every account, auto-categorizes transactions and pushes real-time financial updates.

The public-data read. The headline 169,380 searches/mo looks enormous but it is at only 8% transactional intent (KD 58) - that is consumer informational traffic, people Googling "budgeting" and "track my money," not buyers shopping for a paid app, so the real demand is a small slice of a big number. The competitor set is brutal and named: Monarch Money, Copilot Money, Rocket Money and YNAB all already link accounts and categorize spending, and Plaid owns the aggregation rails everyone including Gravy must rent. The best pain quote is the r/mintuit lament after Mint died - "without [budgeting features] it's just a glorified checkbook register" - which shows churned Mint users are up for grabs, but the r/ynab quotes ("granite wall of a learning curve," reconciliation gaps) show the switchers are demanding and the post-Mint refugees already flowed to Monarch and Copilot. Funding is COOL (1.0/10) and the funding records are largely off-category noise (Stash, Pleo, Nuula, Tinvio are not direct personal-finance-agent competitors), so category capital is hard to read here. The scraped price floor of $7/mo is real but consumer personal-finance is a famously low-retention, high-CAC graveyard.

What it does. An agentic ERP for supply-chain operations that automates exception handling, replenishment, and procurement workflows.

The public-data read. The intent profile is excellent — 5,790 searches/mo at 100% transactional, an unusually low KD 2, and a fat $30.77 CPC signaling real budget — paired with STRONG 20/20 monetization and HOT funding (DualEntry $90M, Doss $55M). The weakness is the one the dossier flags itself: competition is TOUGH at 9.6/24 with 10 named incumbents, and they are heavyweights — Blue Yonder, IBM Supply Chain, Descartes, project44, Pando, Locus. The most useful pain quote is buyer-shaped and points straight at that wall: r/Warehousing, "Blue Yonder is going to be way more complex, expensive and difficult to implement." That's a switching opportunity gated by incumbent depth, not greenfield. Monetization shows no price and a "None" payback against a $308-1,026 CAC, so the unit economics are unanchored — the headline is intent, not proven ARPU.

What it does. real-world agent testing

The public-data read. Near-zero search (30/mo), pure category creation, against a fast-growing eval cohort (Braintrust, Arize Phoenix, Promptfoo, Galileo). The r/AI_Agents pain ("what does your stress testing look like") is real curiosity, not budget yet.

What it does. Provider-credentialing service that gets healthcare providers in-network fast with two-day payer submissions.

The public-data read. This is the strongest entry in the group and it earns it on demand, not hype: 380 searches/mo at a remarkable 97% transactional intent, KD 19, trend up, across 4 countries, with the dossier flagging the only real risk as a crowded SERP. The pain is genuinely burning and well-sourced - r/Residency's "even small errors or missed deadlines can set credentialing back weeks, and most providers don't have the time to chase down every detail" and an r/CodingandBilling team describing "the pain of credentialing 800 providers/mo with thousands of tasks" - so the job-to-be-done is real and budgeted. The catch is the competitor wall: Availity, Symplr, VerityStream, CAQH, and especially the well-funded Medallion already automate credentialing and payer enrollment, so "two-day submissions" is a speed claim against incumbents, not a new category. The funding pillar is a middling 5.5/10; Apploi ($25M, healthcare hiring/onboarding) is a plausible adjacent comp while Headway and Ambience are different categories, so the directly-comparable capital is modest and the space is competitive rather than greenfield. The reimbursement/regulatory nuance the score misses: payer submission timelines are gated by the payers themselves and by NCQA/state rules, so a "two-day" promise is partly outside the startup's control - the bottleneck is often the payer's queue, not the paperwork.

What it does. AI-native technical assessments that score how engineers actually use AI, via session replay and "reliance scoring," rather than grading final code.

The public-data read. Top LRS in the batch, and the timing is genuinely sharp: demand growth is "leading" (+1.79 diff), 57% transactional intent, KD 20, and BURNING pain anchored to dead-on quotes, the r/ycombinator "what's your interview assignment for AI engineers" thread, r/csMajors on candidates cheating with Cluely, and the HN DevDay post ("we hire engineers like it's 2015"). The wedge, scoring AI-reliance, is a real 2026-native angle that HackerRank, Codility, HireVue, TestGorilla, SHL, and CodeSignal don't natively measure. But it's a crowded assessment market with 10 direct competitors, and the economics are thin in the SaaS case (18% churn, $14,400 avg annual revenue, $900 CAC at $20-99/mo entry); the API model's $6M-40M revenue case rests on aggressive 5,000-20,000 candidate volume.

What it does. Agentic teammate for public-equities investment teams that tracks names across many differentiated datasets.

The public-data read. This is the strongest demand profile in the accounting-tagged set - 360 searches/mo, 60% transactional intent, KD 29 (very workable), budget-proof 10/10, and a 26/30 "burning" social-pain score - though note the sector tag is wrong; this is buy-side investment research tooling, not accounting/tax. The competitors are the real moat problem: AlphaSense, BamSEC, Quartr, and Koyfin already own filings search, transcripts, and analyst workspaces, and the dossier flags "Established players dominate SERP" as the top constraint. The most on-topic pain is the Quora thread asking whether AI can "really be used to trade legally the markets... with most accuracy," which exposes the buy-side trust problem more than a workflow gap - analysts distrust AI accuracy on names they are responsible for. The scraped $100/mo price and 60% intent suggest a real willingness to pay. Category capital is genuinely hard to read here: the funding records are badly contaminated (the extractor pulled OpenAI's $6.6B and First Brands, an auto-parts company), so do not treat those as competitors or as a category-capital signal - the only plausibly-relevant record is EnFi's $15M, which is too thin to draw conclusions from.

What it does. A workspace where teams of AI agents coordinate and complete work together for SMBs.

The public-data read. Highest demand pillar in the batch (30/35, leading growth diff +1.741), Funding HOT (8.5/10, $636M category total incl. Rippling $450M, Avoca $125M), and 10/10 budget proof (BCG: AI sales agents lifted free-trial signups 78%). But the cracks are structural: search is only 160/mo, Barrier to Entry 12/24 TOUGH, and the competitor wall is Microsoft, Slack, Glean, Monday, Asana, Dust, and Lindy, incumbents that will bundle multi-agent coordination for free. Social pain is the weakest in the batch (16/30 CHRONIC, Neutral), and the most telling quote is the inverse of the thesis: r/AI_Agents, "the agent collab platform might be the wrong bet... small elite teams that effectively utilize agents may not need AI Slack." The monetization line is alarming: a $6/mo price floor and a 127.2-month payback (the worst in the cohort), with CAC $282-939 against a $120-420 ARPU white-label model.

What it does. Actuarial intelligence that helps corporate risk managers quantify exposures and optimize premium spend.

The public-data read. Strong demand and monetization profile - 1,440 searches/mo, a striking 100% transactional intent, budget-proof 10/10, monetization 20/20, and a "burning" 25/30 social-pain score - making this one of the better-scored ideas in the batch. The competitor field is thin but heavyweight: only Marsh McLennan and Verisk are named, and those are the global risk-advisory and risk-data incumbents whose actuarial models and corporate-risk tooling are exactly what Huscarl wants to disrupt - a thin list of giants is harder to dislodge than a long list of startups. The most on-topic pain is the r/projectmanagement thread on "actual quantifiable ROI for risk management," which signals the buyer struggles to justify risk spend - which is Huscarl's pitch - but the other pain quotes are generic Indie Hackers software-testing noise, so the social-pain score looks inflated by off-topic mentions. The scraped $50-$135/mo price plus 100% intent suggests a real, defined buyer (the corporate risk manager). Category capital is only partially readable: Equisoft ($125M, insurance/investment software) and Corgi ($108M) are plausibly adjacent, but Marshmallow (consumer digital insurer) and Inclined (policy-backed lending) are off-target, so the funding list overstates how directly comparable the capital is.

What it does. AI scheduling and dispatch for short-haul trucking fleets.

The public-data read. Decent intent on thin volume — 2,040 searches/mo at 100% transactional, KD 28, with a strong $47.94 CPC — but this is a CROWDED-BUT-DOABLE field (13.2/24) against ten named TMS/dispatch players, including a genuinely threatening AI-first peer: TruckSmarter (free-to-start, chat-based, and freshly funded at $16M from Thrive), DispatchMVP (voice dispatch), Truckbase, and the enterprise wall of McLeod and Trimble. The killer is unit economics: a $12-$998/mo price (observed: TruckSmarter $49, Truckbase $290, DispatchMVP $12-$998) against a $479-1,598 CAC yields a 26.5-month payback — far too long for an SMB-fleet self-serve motion. Pain is also the weakest link: CHRONIC 20/30 at Neutral intensity, and the "top complaints" are off-target — Indie Hackers AI-bubble musing and an r/ProHVACR dispatch thread, not short-haul truckers in pain. The dossier has no founder wedges and a vague "build relationships with investors" next move, which is a tell that the vertical isn't yet sharpened.

What it does. Lets founders generate and A/B test personalized ad campaigns across hundreds of audience personas.

The public-data read. The standout number is 100% transactional intent on 380 searches/mo with a 0.2-month payback and CAC of just $27-90, the cleanest unit economics in this batch. But it lives against AdCreative.ai, Smartly.io, Pencil, Omneky, VidMob and Sprinklr, all funded ad-creative incumbents. Funding scores 2/10 COOL: the category's flagship, Pixis, raised $85M from SoftBank back in Sep 2023 and the space has gone quiet since. Social Pain is 21/30 but High evidence quality, with real switching-shaped complaints on r/FacebookAds ("low spend $125-200/day, just using one campaign") and r/AskMarketing. The risk is not economics, it's that "persona variation" is a feature AdCreative.ai can ship, not a company.

What it does. An open-source, self-hosted workspace for SMB teams to run AI agents with their own models, tools, and guardrails.

The public-data read. High intent on a near-empty search pool: 10/mo searches (US-only, 100% transactional, KD 5), so the report itself says validate with paid pilots and pre-sells, not content. Pain is real and well-sourced (21/30 CHRONIC, Frustrated) with strong HN/Reddit evidence: builders wanting agent attribution, control, and auditability ("you can't really control how they do it or what they're allowed to access. That's risky"), and an r/aiagents post about building a self-hosted multi-agent workspace. The competitive set is brutal company to keep: Anthropic, GitHub, plus OpenClaw, Eigent, and other framework players, in a market where open-source self-hosting is more often free than paid. Monetization is the weakest pillar (16/20 WORKABLE, $5-200/mo, 5.1-month payback), and the budget-proof comps (Buildkite, Azure self-hosted agents) are CI/CD infra, not agent workspaces, an adjacency stretch.

What it does. AI-native customer-success signals that predict churn and surface engagement risk for mid-market B2B CS teams.

The public-data read. Strong intent profile, 1,140 searches/mo at 93.8% transactional, KD 19, with a BURNING 24/30 pain and "churn prediction software" rankable at KD 0. But the category is owned by Gainsight, ChurnZero, Planhat, Pendo, Mixpanel, Totango, and Vitally, and the most quotable pain is incumbent-hatred ("As a Gainsight admin of ~10 years, I hate this platform," "I hate ChurnZero CS ops"), i.e. a rip-and-replace opportunity gated by deep switching costs. The monetization line is alarming: $8/mo price against a $307-$1,024 CAC gives a 208 month payback, so the real business is clearly the file's $99-$60,000/yr model, not the headline price. Funding is COOL (1/10), and the r/CustomerSuccess "we're at $10M revenue and get along great just using HubSpot" quote is the real demand ceiling.

What it does. On-brand AI design partner that generates tailored, brand-consistent marketing content on an hourly cadence for SMBs.

The public-data read. This is a knife fight in the most crowded creative-software category alive: Canva, Adobe Express, Jasper, Writer, Typeface, Kittl, Piktochart, Ocoya. Demand is lukewarm and low-intent (480 searches/mo, 8.0% transactional, KD 38) and the funding is COOL (1.5/10). The pain is real and specifically anti-incumbent, the best signal being the r/canva exodus threads ("so tired of the new update... can't get anything done," "sad after 10 years having to search alternatives"), which is a churn opportunity not a greenfield. Pricing spans an absurd $1-$4,185/mo, so the "$18.40 CPC, $184-$613 CAC, 0.2 month payback" claim is unanchored. The "hourly on-brand content" cadence is the only real wedge and it's unproven.

What it does. Embeds privacy-compliance enforcement directly into the codebase for mid-market B2B companies.

The public-data read. 410 searches/mo at 100% transactional intent and HIGH evidence quality is genuine buying signal, but it sits against OneTrust, TrustArc, Securiti, DataGrail, Osano, Ketch, Transcend and BigID, a deeply entrenched privacy-compliance field (Barrier scored 10.8/24 TOUGH). The monetization is the worry: $135/mo headline but an Avg CPC of $32.58 driving CAC to $326-1,086 with a 6.5-month payback. Social Pain quotes are strong and switching-shaped ("What's the best OneTrust alternative for privacy," r/cipp; fintech buyers on r/fintech), which is real, but those buyers want a OneTrust replacement, not necessarily code-level enforcement. Recent funding is WARM but modest (Ankar $20M Dec 2025, Bayshore $8M Jun 2026).

What it does. sandboxed agent runtime

The public-data read. Huge search (311k/mo) but KD 71, and most of that volume is generic "runtime," not your category. E2B, Daytona, Runloop and Modal are well-built and developer-loved. Pain is neutral.

What it does. Helps manufacturers discover and source suppliers for industrial goods.

The public-data read. The standout signal is pain — BURNING 25/30 at High evidence with switching-shaped quotes, the sharpest being r/AmazonSeller: "Does everyone source their products on Alibaba? Is there an alternative? It was fine for a while but we are looking into launching a new more expensive..." That's a real, frustrated, paying buyer hunting for an exit. But demand volume is tiny (440 searches/mo, though 100% transactional and a very high $124.78 CPC), competition is CROWDED-BUT-DOABLE (10.8/24) against Alibaba, GlobalSources, ThomasNet, TealBook, and Faire, and funding is COOL (1/10) with the nearest comps (Diagon $12M 2024, Sourceful $12.2M 2021) modest and old. The economics are the worry: a marketplace model at $39-$2,999/mo (MakersRow's anchor) against a $1,248-4,159 CAC gives a 2.2-month payback only if you believe the high-ARPU tier — at the $39 entry that math collapses.

What it does. AI-driven applicant screening plus proactive talent sourcing that builds a pre-vetted pipeline for mid-market B2B, without replacing the full ATS.

The public-data read. This is the rare warm one with real teeth: 17,020 searches/mo at 80% transactional intent and a low KD 14, plus BURNING pain (25/30) and 9/10 budget proof, the strongest evidence stack in the batch (Gem/Airbnb, Eightfold/Tesla, Greenhouse/Spotify, Findem/Boeing, Phenom/Walmart). The catch is it walks straight into Gem, hireEZ, Findem, Greenhouse, SmartRecruiters, Lever, Workday, and Phenom, all funded and entrenched. Monetization is strong ($720-14,995/mo, 2.4-month payback) but CAC is heavy at $645-2,152 on a $64.55 CPC, demanding an outbound, not PLG, motion despite the "PLG founder" label. The r/recruiting threads ("anything better than Greenhouse?", "ATS universally terrible") show real switching appetite.

What it does. AI assistant that helps businesses get insured by understanding coverage, comparing quotes, and reviewing policies.

The public-data read. The demand headline is the best in the batch - 1,850 searches/mo and 91% transactional intent, demand 30/35 - but the fundamentals beneath it are the worst combination here: KD is 68 (brutally hard to rank), the trend is sharply negative (-0.72), and the dossier flags "established players dominate SERP" as the top constraint. The competitor wall is dense and well-funded: Bold Penguin, Simply Business, Coverdash, Tarmika, and Next Insurance already own digital commercial-insurance comparison, quoting, and placement - the exact workflow Kinro describes. The most on-topic pain is the r/Insurance_Companies small-business owner realizing "i probably need proper commercial insurance instead of just hoping nothing bad happens," which is genuine top-of-funnel demand, but it is a buyer who needs guidance, not necessarily one who pays a SaaS fee versus just using a free broker. Category capital is real and on-topic: WithCoverage ($42M Series B), FurtherAI ($25M), Sixfold ($30M), and Liberate ($50M) are all AI-insurance-ops raises, signaling heavy money flowing into AI insurance automation. The regulatory reality the score ignores: "AI insurance broker" means Kinro likely needs a licensed producer/broker in every state it places business, plus carrier appointments and a commission/compliance model - or it is just a lead-gen front for licensed brokers, which is a much weaker, commoditized business.

What it does. Turns a technical team's product work into SEO content and inbound pipeline through a repeatable workflow.

The public-data read. The numbers are healthy where it counts: 380/mo searches at 60% transactional, KD median 5/100 (and an "inbound marketing software" term at KD 4), Funding 10/10 HOT ($223.2M across 5 raises incl. Hightouch $150M May 2026), and a stated 0.1-month payback. But the pain score is the softest part of the story: 21/30 CHRONIC at Neutral intensity, and the "top complaints" pulled from r/content_marketing and r/technicalwriting are about career advice and a Stack Overflow siesta bug, not buyers screaming for this. They are also wading into an agency-saturated lane: Animalz, Grow and Convert, Ironpaper, Directive, Column Five all sell content-to-pipeline today. CAC of $405-1,350 against a $113-$80,000/mo price range is wide enough to hide a real business or a services trap.

What it does. control center for agents

The public-data read. 930/mo but intent is LOW (8% transactional), people research agent platforms, they do not buy them. Up against Dust, Glean, Microsoft and Salesforce.

What it does. Global banking and payments API/CLI that lets teams and AI agents open accounts and automate payroll, invoices, and payouts across borders.

The public-data read. This is the strongest demand profile in the payments cluster: 1,490 searches/mo at a striking 90% transactional intent and a soft KD 24, with a perfect 10/10 budget-proof and a scraped band that tops out at $31,000/mo. The problem is the competitive set is brutal and well-funded: Airwallex, Wise, Payoneer, and dLocal all sell multi-currency accounts with cross-border payout APIs, and the dossier's own top constraint flags that established players dominate the SERP. The best on-topic pain quote, from Indie Hackers, is honest and damning: "the hardest issues usually arise at the local level. A transfer may leave one country..." which is exactly the licensing-and-rails problem incumbents spent a decade and hundreds of millions solving. Among the category-capital records, NALA ($10M seed, cross-border payments/payroll) is a plausible direct comp; the others (Pagos, Teampay, CapitalOS) are spend-management or payments-intelligence and read as off-wedge noise. The unscored reality dominates everything: opening real bank accounts and moving payroll internationally requires money-transmitter or e-money licenses across multiple jurisdictions, so the "agent" framing is a thin layer on top of a regulatory mountain.

What it does. story-based code review

The public-data read. 740/mo, 100% transactional, but payment signal is WEAK and the lane is crowded (CodeRabbit, Qodo, Graphite, Greptile). EU AI Act is a weak "why now."

What it does. label-free fraud detection

The public-data read. Solid intent (1,230/mo, 100% transactional) and a real tailwind ("pig butchering an emerging risk for financial institutions," Coinbase hiring identity ML). But Sift, SEON, Fingerprint and Signifyd are entrenched, and the 225-month payback signals broken CAC/ACV assumptions.

What it does. multi-agent coding orchestrator

The public-data read. Tiny search (260/mo) but an honest pain quote on Indie Hackers ("multi-agents produce code that doesn't fit together"). Brutal competition: Claude itself, plus Verdent, Zencoder, Claude Squad.

What it does. agent-era observability

The public-data read. 260/mo, KD 38, into Datadog, Sentry, Grafana and Axiom. The graveyard is loud: Observe ($50M, 2023), Observe.ai ($125M, 2022), Lumigo ($29M, 2022), all funded, none dislodged Datadog. SEC AI compliance is the "why now."

What it does. Tool that finds and quantifies which repetitive veterinary-clinic tasks to automate, sitting on top of existing PIMS as a discovery layer.

The public-data read. The headline 3,090 searches/mo and leading growth are misleading: that volume is the generic "find what to automate" head term, while purchase intent is LOW at 8% and KD median is 57. Pain is the weakest in the batch at CHRONIC 16/30, and the one genuinely on-vertical quote is the r/Veterinary thread from a software engineer who "noticed the practice was slowed down" by their systems, which is observation, not a buyer in pain. The vet stack is crowded with Otto.vet, PetDesk, Vetstoria, Weave, IDEXX and Covetrus, and the "similar ideas" (Celonis, UiPath, Automation Anywhere, Zapier) reveal the deeper risk: process-mining for SMB clinics is a heavy enterprise concept squeezed into a $49-$1,000/mo SMB wrapper. Payback reads 0.2 months on a tiny $36-$120 CAC, which is implausible for a product that requires connecting to clinic systems.

What it does. access control for agents

The public-data read. Good intent (1,760/mo, 99% transactional, KD 9, easy to rank) and perfect timing ("Cisco rolls out tools to protect IT systems from AI agents"). But that headline is also the threat: Okta, Cisco and OneIdentity are moving in, and barrier-to-entry is TOUGH (10.8/24).

What it does. Agent-native autonomous operations software that plugs into existing ERPs for industrial distributors.

The public-data read. Strong pain (BURNING 25/30, High evidence) and a clean entry path (KD 7) on near-empty demand — just 300 searches/mo at 65% transactional. Competition is genuinely TOUGH (7.2/24): the named set is the full distribution-ERP wall — Epicor Prophet 21, Infor, Dynamics 365 BC, NetSuite, Acumatica, SAP S/4HANA — and the dossier even lists "Hexa" as agent-native plugging into those ERPs, which is the wedge. The recurring pain quote is the ERP-replacement lament on Quora: "Is there any similar ERP solution like SAP, which is cheaper, but not at all lower in quality?" The economics are split: CAC is low ($55-185), but the $1-$999/mo price (Cin7's $349-999 anchor) produces a 33.3-month payback — too long for the entry tier, so the real business is the high-ARPU distributor contract. The four wedges (industrial-parts quote-to-order, building-supply RFQ assist, foodservice reorders, auto-parts backorders) are sharp and the right altitude.

What it does. Document-processing agent that automates extraction, validation, approval routing, and ERP writeback for mid-market B2B.

The public-data read. Best raw demand in the batch, 5,360 searches/mo at 99.8% transactional, KD 15, leading growth, but the incumbents are the heaviest possible: UiPath, ABBYY, Rossum, Nanonets, Hyperscience, Kofax, Automation Anywhere, plus Azure Document Intelligence, and all eight budget-proof citations (Box, UiPath, NVIDIA, LlamaIndex) describe Walter's exact "read, validate, route, write-to-ERP" flow as already shipping. The fatal number is the headline: $25/mo (file body uses $1-$18,000/mo) against a $512-$1,708 CAC yields a 55.5 month payback. The honest model the file lands on, vertical at $18k-$96k/yr, is the only path. The r/QualityAssurance produce-distributor ERP story is the kind of narrow, costly workflow worth owning.

What it does. GEO for AI agents

The public-data read. Almost no search (80/mo) but a real emerging behavior (retailers building AI-scrapable sites, Shopmonkey hiring a GEO manager). Writesonic, Profound and Semrush are already pivoting to GEO. Best unit economics in the batch (0.2-month payback).

What it does. Automated, large-scale data labeling and synthetic data generation for robotics AI.

The public-data read. This is the soft one in the robotics cluster: demand is only 140 searches/mo at LOW 8% transactional intent (researchers, not buyers), pain is CHRONIC 17/30 at Neutral intensity, and funding is COOL (1/10). It walks into a brutal, well-funded data-labeling field — Scale AI, Labelbox, Roboflow, V7, Encord (which already owns 3D/LiDAR/sensor-fusion, exactly the robotics niche), Superb AI, SuperAnnotate. The most honest pain quote is generic: Quora's "What's hard about data labeling?" — that's a research query, not a budgeted complaint. Monetization looks fine on paper ($630/mo, 1.0-month payback, $112-373 CAC), but with 8% purchase intent and a 10-deep competitor wall led by Scale, the question isn't economics — it's whether "robotics-specific labeling" is a feature Encord and Roboflow ship rather than a company.

What it does. backend for coding agents

The public-data read. Tiny search (50/mo) in a hot space (Supabase, Firebase, Convex, Appwrite, mostly free tiers). "Agent-native backend" is the wedge; the risk is Supabase ships agent primitives and you are a thin layer. Great payback (0.4 mo) if usage converts.

What it does. AI talent agent that delivers warm job intros directly to candidates, bypassing job-board search and recruiter spam.

The public-data read. Demand is weak and the wrong shape: 90 searches/mo at only 8.0% transactional intent, KD 67, and the incumbents are the entire hiring internet (LinkedIn, Indeed, ZipRecruiter, Wellfound, Hired, Ashby). The pain is loud and real on r/recruitinghell and r/ITCareerQuestions ("applying on Indeed feels like a void of nothingness"), but that is candidate pain, and candidates don't pay; the file says employers pay, which is a two-sided cold-start. CAC $47-$155 with a 1-month payback looks great but rests on a $2-$250/mo price range so wide it signals no real ACV anchor. The "how to get job referrals" KD 1 keyword is the only crack worth probing.

What it does. instant market insights

The public-data read. Strong demand (10.9k/mo, 93% transactional, KD 28) but a brutal incumbent set (Kantar, NielsenIQ, GWI, Attest). Funded challengers stalled: Zappi ($170M, 2022), GetWhy ($34.5M, 2024). The FTC-Instacart headline is unrelated.

What it does. team coding with agents

The public-data read. 50/mo, MEDIUM intent, into the apex predators (Cursor, GitHub, Windsurf, Replit). "Make your team AI-native" is positioning, not a moat.

What it does. Prime brokerage for prediction markets offering professional execution across Kalshi, Polymarket and others.

The public-data read. This is the strongest-demand project in the group (Demand 30/35, 150 searches/mo at 50% transactional intent, rising trend, budget-proof 10/10), and unusually the funding records are real category signal: Kalshi's $185M, $300M and $1B raises are genuine and confirm institutional capital is pouring into the prediction-market venue layer - but read that as a CATEGORY signal (the rails River would broker on are exploding), not a competitor River must beat. The named competitors frame the ambition precisely: Polymarket (the venue), and traditional prime brokers Marex, Clear Street and TradeStation (the model River is porting). The single best pain quote is the r/arbitragebetting trader running automated Kalshi/Polymarket arbitrage who says "the main pain was always execution... detect the edge then by the time you've [acted it's gone]" - that is a real, specific, professional buyer with money. The scraped price band ($1 to $2M/mo) is uninterpretable. The unscored gating factor is enormous: prime brokerage for event contracts touches CFTC-regulated venues (Kalshi) and offshore crypto markets (Polymarket) simultaneously, so the licensing, custody and AML stack is the actual product, and it is the hardest part.

What it does. A continuously self-improving firewall that defends AI applications against prompt injection across major agent SDKs.

The public-data read. Note the sector tag is misleading — this is AI security, not space/frontier; auto-tags are unreliable. Monetization is STRONG (19/20) and funding WARM (5.5/10, with Irregular's $80M Sep 2025 nearby), but demand is thin and low-intent: 170 searches/mo at just 8% transactional, KD 30. Competition is CROWDED-BUT-DOABLE (15.6/24) against a real AI-security field — Lakera, Prompt Security, Pangea, NeuralTrust, HiddenLayer, Rebuff. Pain is the weak pillar (CHRONIC 17/30, Neutral, and notably "payment None"), and the quotes are developer chatter, not budget holders — the most on-topic is an HN user asking "how... to prevent prompt injection attacks and trifecta attacks," which is a builder seeking a technique, not a buyer with a PO. The $49-$500/mo price (PromptLayer's anchor) against a $325-1,083 CAC gives a 3.2-month payback only at the high end.

What it does. AI-driven global product-compliance platform that maps products to regulations and generates audit-ready documentation for SMB/DTC brands.

The public-data read. The best-balanced profile in the batch and one of few flagged "proceed": demand is WARM 25/35 with HIGH 50% purchase intent, HIGH keyword depth and strongly leading growth, plus BURNING social pain (25/30, "Frustrated") with 10/10 budget proof. Volume is thin at 270/mo, but the pain quotes are on-target, the r/fintech thread "most failures in compliance automation come from edge cases, silent UI changes, or missing context a human analyst would catch" and the r/AMLCompliance "processes are slow, repetitive." The competitor set is broad (Reglyr, Trace One, SGS, Compliance.ai, Hyperproof, Vanta, Credo AI), notably mixing security-compliance (Vanta) with product-compliance, which suggests Complir's true wedge (cross-border DTC product compliance) is less directly contested than the LRS competitor list implies. Funding is COOL (1.5/10; Compliance.ai $6M, Dataships $7M, Leapfin $12.2M). The $27-$90 CAC and 0.1-month payback are implausibly rosy and reflect the cheap $2.69 CPC, not the real enterprise-only pricing the file admits most vendors use.

What it does. An AI assistant that books meetings automatically by learning your preferences, pitched to busy SMB founders.

The public-data read. Demand is LUKEWARM (19/35, 130/mo, 8.0% transactional) but the killer stat is KD median 75/100, this is one of the highest-difficulty keyword sets in the batch, sitting directly under Calendly, Chili Piper, Clara, Kronologic, Reclaim.ai, Howie.ai and Lindy. Funding momentum is COOL (1.5/10) yet budget proof is 10/10 with named payers (Calendly, Chili Piper, Reclaim, Motion, Clockwise), and payback is an implausible 0.1 months off a $5.79 CPC and $58-193 CAC. Notably the file shows Salesmsg and RevOps.ai already shipping "Booking AI Agent" features that integrate Calendly, the exact wedge, as add-ons inside existing products.

What it does. AI agents that run vacation-rental operations — handling guest communications and coordinating the team on autopilot.

The public-data read. The bright spot is BURNING pain (25/30, High evidence) with the most buyer-shaped quote in this cluster: r/AirBnBHosts comparing tools directly — "I've tried out Hospitable. They have much better UX and some better features. However they have their fair share of bugs as well." That's an active switcher. But demand is LUKEWARM (24/35, 320 searches/mo, though 100% transactional) on a hard-to-rank KD 48, and the competitor wall is deep and funded: Guesty, Hostaway (a $365M strategic raise in 2024), Hospitable, Breezeway, Lodgify, plus AI-native peers Host Buddy AI and Enso Connect. The economics are the alarm: a $1-$99/mo price (observed: Guesty/Hostaway at $1-9, Hospitable $5-99) against a $624-2,081 CAC produces a 187.8-month payback — the worst in this cohort and structurally fatal at the SMB tier, which the dossier itself concedes ("the economics at $9/mo are too thin").

What it does. GPU apps in cloud

The public-data read. Tiny search (100/mo) but KD 70, only 3 direct comps, in a market dominated by CoreWeave (raised $2.3B in 2023) and Lambda. Real niche pain on r/Cinema4D ("4K renders taking 7 hours"). Flat $9/mo with a 57-month payback.

What it does. customizable agent IDE

The public-data read. Decent search (3,770/mo) but it is an interface on top of "the Pi coding agent," heavy platform dependency, against Cursor, Windsurf and Anthropic.

What it does. Runs background workflows like fax intake, patient calls, scheduling, and prior auth for specialty medical practices.

The public-data read. Top LRS in the batch (53.1) on the strength of 7,830 searches/mo at 100% transactional intent and a "BURNING" 25/30 social-pain score, though the headline search figure likely blends practice-admin and generic EHR queries. The named competitors are the heavyweight incumbents that already own this workflow: Athenahealth, DrChrono, Kareo (practice management/EHR) and Waystar (RCM + prior auth automation) - so Plena is automating tasks inside categories where billion-dollar vendors already sit. The most on-topic budget signal is the Indie Hackers note that "Startups specializing in AI-powered billing are quickly gaining traction among providers frustrated with manual claim workflows," confirming providers are actively frustrated and spending; the r/HealthTech integration-pain quote reinforces that wiring into existing systems is the hard part. Budget-proof drops to 7/10 (lowest credible in the batch) but the wide scraped band ($30-$6000/mo) fits a practice-level service sale. Category capital is partly readable: Kareo ($55M series C, "practice management," rel=0.97) is a direct legacy comp, and Emitrr ($4M, business text automation, rel=0.86) is a plausible adjacent - while Talkspace/Glooko are noise. That a direct incumbent like Kareo raised heavily yet the prior-auth/fax-intake pain still burns is a category signal that the work is genuinely hard, not unaddressed.

What it does. Builds human-level intelligence systems for robots.

The public-data read. This is a frontier-hardware play where the public-data lens is almost useless and the numbers should be read with heavy discount. Demand is 40 searches/mo (the dossier flags "low search volume" as the top constraint), and the named competitor set is the most capital-saturated wall imaginable — Physical Intelligence (which just raised $1B in April 2026), Figure AI, Tesla Optimus, Boston Dynamics, 1X, Agility, Apptronik. Pain is CHRONIC 17/30 at Neutral, and the quotes are abstract Quora-grade ("What are some potential problems that can hamper the real-world use of robotics?") plus a deflating r/robotics thread titled "robotics industry is dead — a bad choice for jobs." Monetization is nominally STRONG with a 0.1-month payback on $172-572 CAC, but that is SaaS math pasted onto humanoid hardware priced "$20,000-$50,000" or sold via enterprise contract — discard the payback. The funding pillar scoring 10/10 HOT is really a category signal: a flood of capital ($1B + $405M + $500M + $110M among peers) chasing robot foundation models that haven't broken out commercially.

What it does. Automates hardware compliance by mapping standards, drafting lab-ready documentation, and matching teams to vetted testing partners.

The public-data read. This is a rare "proceed" decision, demand WARM (26/35, 100% transactional) and social pain BURNING (25/30, 39 mentions across r/soc2, r/grc, r/regulatoryaffairs, r/hwstartups), but only 50/mo searches and a hardware-build penalty (LRS -2). The competitor set is the SOC2/ISO automation incumbents (Vanta, Secureframe, Sprinto, Drata, Hyperproof, AuditBoard, LogicGate), none of which own hardware/device certification specifically, which is the actual wedge. The glaring red flag is the monetization signal: price reads $1/mo with a 1,139-month payback against a $42.06 CPC and $421-1,402 CAC, the file itself flags this as broken and tells the founder to "prove a price floor far above $1/mo." Funding is COOL (3.5/10), category Hot ($77M, incl. Delve $32M Jul 2025).

What it does. An AI hedge fund that trains frontier financial models to discover and trade on new market signals within risk limits.

The public-data read. On the 6 signals this looks like the batch's demand standout: 2,260 searches/mo, 48% transactional intent, the lowest KD in the cluster at 21, BURNING social pain (25/30), and an upward trend, with a scraped band up to $6,195/mo. But the framing is the catch: this is described as "an AI hedge fund," not a SaaS tool, and a hedge fund's "customers" are LPs allocating capital, which the search-volume lens does not measure at all. The competitor set makes the difficulty explicit: Two Sigma, AQR, Man Group, and XTX are among the most sophisticated quant shops on earth, and Numerai already productized the "AI-driven hedge fund" model, so Standard Signal is claiming to out-research firms with decade-plus head starts and billion-dollar compute budgets. The most on-topic pain quote, from r/algotrading, is sober: "Fully autonomous is possible, but most systems still need guardrails and monitoring. Markets change faster than models adapt," which is the central technical risk of the whole pitch. Category capital is hard to read cleanly: the records (Allasso options analytics, Nilus treasury, Arva AML, Utila digital-asset ops) are fintech-adjacent but not AI-hedge-fund comps, so public funding does not reliably map to this category. The unscored reality is decisive: running a fund means SEC investment-adviser registration, custody and audit infrastructure, and a multi-year track record before serious LPs allocate, none of which a search-demand score can see.

What it does. Clinical-trial data-management software that auto-generates eCRFs and source documents for faster, compliant submissions.

The public-data read. Demand is thin and shrinking (90 searches/mo, KD 9, trend negative) but intent is pure (100% transactional), so the few people searching are buyers, not browsers. The named competitors are the entire entrenched CDMS oligopoly: Medidata, Veeva (Vault CDMS), Oracle (Clinical One), plus open-source REDCap and OpenClinica. The single sharpest pain quote is from r/clinicalresearch: "Veeva CDMS is one of the worst EDC systems I've used. coming from Medidata RAVE cades into the past. It's a horrid system" - real switching anger toward the incumbent, which is the wedge. Budget-proof is 9/10 with a scraped price band of $275-$3750/mo, and the buyer (pharma/CROs) clearly has money. The regulatory barrier is the real story the 6-signal score underweights: eCRF auto-generation has to survive FDA 21 CFR Part 11, audit trails, and sponsor validation - selling "faster, compliant" to risk-averse CROs is an 8-24 week (Fluenta's estimate) trust sale, and category capital is hard to read cleanly since the funding records (OpenEvidence, AKASA, Eleos) are adjacent-health megadeals, not direct EDC competitors.

What it does. Pairs an ex-FDA regulatory team with an in-house AI platform to accelerate FDA filings across 510(k), PMA, IND, and more.

The public-data read. Panacea has by far the highest demand in the batch - 19,510 searches/mo at 100% transactional intent, KD 19 - but that number is almost certainly the broad "FDA approval" informational query rather than buyers shopping for a regulatory-filing service, so treat the headline volume with caution. The named competitors are mostly miscast: Recursion, Insitro, and Generate Biomedicines are AI drug-discovery biotechs, not regulatory-filing services, with only Medidata being a plausible data adjacent - so the real competitive set (regulatory consultancies, CROs, Enzyme-style software) is under-represented. The most relevant quote is the brutal Quora reality check: "The FDA approval process for bringing a new pharmaceutical to market can span anywhere from 5-20 years" - which both proves the pain and exposes the risk that "accelerate" has hard regulatory limits no AI removes. Budget-proof is 9/10 but the scraped price ($40-$85/mo) is wildly mismatched to a service that should command consulting-grade fees, so monetization is unclear. Category capital is legible at the right end: Enzyme ($2M seed, "FDA compliance software for startups," rel=0.98) is the clean comp, and that this most-direct competitor only ever raised a small seed without breaking out is itself a category signal - FDA-filing software is a slow, services-heavy market - while the Tempus/Aidoc megadeals are noise.

What it does. learning memory for agents

The public-data read. 120/mo, intent LOW (8%), the same crowded memory thesis as Memory Store and Wato in this batch (mem0, LangChain, LlamaIndex, Pinecone). Good payback (2.6 mo) if it converts.

What it does. Speeds up personal-injury case workups by automatically retrieving police reports, insurance coverage, and medical records.

The public-data read. Demand is narrow but high-intent-of-a-different-kind: only 170 searches/mo at 8% transactional and the lowest KD in the batch at 7, so SEO is not the play; this is a partnerships-and-outbound motion into PI firms. The competitive picture is the headline risk: the named comps (Filevine, CASEpeer, Clio, Evisort) are case-management incumbents, but the category capital exposes the real threat: EvenUp ($135M series C) and Supio ($60M series B, plus an earlier $33M) are explicitly "AI platform for personal injury law firms," exactly Andco's lane and already massively funded, with Eve ($47M) adjacent for plaintiffs' firms. That trio is the most legible competitive-capital signal in the entire batch, and it says this niche is not white space; it is a funded arms race. The most on-topic pain quote, from r/LawFirm, is about case-management fit ("Started with casepeer... built for PI") rather than the specific record-retrieval pain Andco solves, so the social signal is adjacent, not bullseye. Monetization scores a perfect 20/20 and the scraped price ($79-$149/mo) is modest, which is suspiciously low for the value if it truly compresses case-workup time. The unscored layer is moderate: retrieving medical records means HIPAA-authorized PHI handling and navigating insurer/police-records gatekeeping, an operational moat more than a licensing one.

What it does. Detects warm leads from buying signals, filters them by ICP, and runs personalized (LinkedIn-first) outreach to book demos for SMB sales teams.

The public-data read. Demand is LUKEWARM (23/35) but on a healthy 1,860/mo at the lowest competition difficulty in the batch (KD 10), though only 8.0% transactional, and it sits under a brutal incumbent stack: Apollo, Outreach, Salesloft, Reply.io, LeadIQ, Smartlead, Instantly, plus Warmly on intent. The standout is that Gojiberry has real traction proof, a published case study claiming "$33K Revenue in 4 Months" and "100+ customers in 60 days," plus 16 Trustpilot reviews at 4 stars, and Monetization scores a perfect 20/20 ($1-$1,999/mo, ~1.2mo payback). Funding is HOT (7/10) but the category comps (Rox $50M Nov 2024, Landbase $30M Jun 2025, Monaco $35M Feb 2026) show heavy capital already chasing "AI SDR."

What it does. iMessage outreach infrastructure

The public-data read. Tiny search (60/mo) into a crowded outreach stack (Apollo, Outreach, Salesloft, Reply) with a serious compliance shadow: iMessage/RCS "at scale" flirts with TCPA and Apple's terms, and Google just tightened RCS spam filtering.

What it does. Autonomous manufacturing of custom mechanical parts.

The public-data read. Bottom of the cluster, and the public-data lens under-rates it in both directions — KD 0 and 100% transactional intent on a tiny 50 searches/mo (the top constraint is "low search volume"), against a TOUGH competition score (12/24) where the named wall is the entire on-demand-manufacturing field: Xometry, Protolabs, Fictiv, Hubs, Machina Labs, Formlogic. Pain is CHRONIC 17/30 at Neutral, and the quotes are textbook-generic — Quora's "What are problems faced in manufacturing processes that can be overcome by innovative designs" — not operators in budgeted pain. Funding is 10/10 HOT, but as a category signal: the comps are robotics-hardware raises (Pudu $150M, Mind Robotics $400M, Mytra $120M), none of them autonomous-machining-marketplace breakouts. Monetization is the giveaway of model-mismatch: a 164.3-month payback on $118-392 CAC, because SaaS math is being applied to a capex-heavy manufacturing operation with per-part pricing from "$1.94 to six figures per project." Discard the payback; the real question is whether autonomous machining can undercut Xometry's vetted-supplier network economics at all.

What it does. AI construction estimating

The public-data read. Good intent (1,400/mo, 82% transactional, KD 13) but the buyer is openly skeptical: r/estimators says "AI just isn't good enough yet." Togal, STACK, ProEst and Buildxact are entrenched.

What it does. no-script app testing

The public-data read. 305/mo, intent LOW (8%), into LambdaTest, Testsigma, Testim and Kobiton, and BrowserStack just hit unicorn status on $200M. Pain quote is a random Gradle build error.

What it does. Gives AI agents rule-based wallets and spending power so they can transact without exposing your real credit card.

The public-data read. Demand is thin: only 75 searches/mo at 36% transactional intent and KD 39 (median), so this is a content-and-community slog, not a search play. The named competitors are heavyweight: Stripe and Ramp already ship programmable cards plus rule-based spend controls, and agent-native entrants Crossmint and Berkeley Payment are building exactly the "wallets + guardrails for autonomous software" pitch. The on-topic pain is real but generic ("What could happen if AI agents are deployed in production without proper guardrails?" on Quora), which reads as engineer anxiety rather than a budget holder begging for this specific product. Budget-proof is 9/10 and the scraped price band ($1-$1,850/mo) shows willingness to pay, but the category-capital records (Lava $6M, SolvaPay $3M, Ralio $2M, all explicitly "payment rails for AI agents") confirm a crowded pre-seed pile-up where nobody has broken out. The unscored killer here is regulatory: holding and moving customer funds drags in money-transmitter licensing, card-issuer/BIN-sponsor relationships, and KYC/AML, none of which the 6-signal score touches.

What it does. A minimalist, AI-assisted food-logging app that surfaces eating-pattern trends without dense nutrition dashboards.

The public-data read. This is the rare consumer play with real top-of-funnel: 4,610/mo searches (highest demand in the batch), leading growth (diff +1.729), KD median 34 with "best food diary app" at KD 20, and a 0.4-month payback. But it is a consumer subscription bloodbath against MyFitnessPal, Lose It!, Cronometer, Noom, Yazio, and CalAI, and Funding is COOL (3.5/10, only $45M category total). The pain quotes are precise and usable, mostly price/friction gripes: r/nutrition complaining MyFitnessPal "entries don't have individual grams," an ADHD user on HN who "built my own calorie tracking app because every other app was just annoying," and Indie Hackers builders explicitly undercutting CalAI on price and accuracy. The unit economics are the worry: only 23.4% transactional intent and a brutal 28-42% annual churn in two of three models, which is the consumer-health-app death rattle.

What it does. Continuously scans AI agents for vulnerabilities and bundles instant insurance coverage for those deployments.

The public-data read. Demand is thin for a "Hot funding" project: only 480 searches/mo at 8% transactional intent (KD 13, easy but informational), and the trend is negative. The competitor wall splits into two species the dossier names: agent-security runtime players (Tigera, Noma Security, CyberArk, SailPoint, SentinelOne) and the actual insurance side, where the funding records are genuinely on-category and rich (Armilla AI $25M and Corgi $108M are real AI-liability/AI-native insurers, Pace $10M is agentic insurance ops, Sixfold $30M AI underwriting). The single best pain signal is the Quora line that an AI CI/CD agent "might decide the best solution is to delete your entire production database," which is a security fear, not an insurance purchase. Budget-proof is 9/10 with a scraped $960-30000/mo band, so enterprises will pay, but underwriting AI-agent risk means becoming (or partnering with) a licensed carrier or MGA, a regulatory lift the 6-signal score ignores entirely. The honest tension: this is a security product wearing an insurance hat, and insurance is the part that needs a balance sheet and a license.

What it does. embeddable app builder

The public-data read. 170/mo into Retool, Bubble, Superblocks and Appsmith. "White-label builder embedded in your SaaS" is a real but thin wedge. Appsmith ($41M, 2022) stalled.

What it does. A real-time global and local regulation tracker positioned as the single source of truth for mid-market B2B compliance teams.

The public-data read. Demand is thin but unusually pure: only 310 searches/mo, yet 100% transactional intent at KD 15, the buyers who search are buyers. The problem is the competitive set is heavyweight legal infrastructure, Bloomberg Law, LexisNexis, Thomson Reuters, IAPP, plus existing trackers from Simmons & Simmons (STRIDE) and White & Case, and the real-name domain regbase.com already exists in slot one. Social pain is only CHRONIC at Neutral intensity (21/30), and tellingly the quoted complaint is a B2B PM in r/ProductManagement asking how to keep up with customer regulatory standards, real, but operational, not desperate. CPC is a steep $75.99 (CAC $760-2,533), and monetization price is listed N/A, which is a gap. The r/gdpr thread, "OneTrust too complex and expensive for startups", is the actual wedge.

What it does. An AI agent that runs in-person events end-to-end, sourcing attendees, personalizing invites, capturing on-site, and syncing to pipeline.

The public-data read. Demand and pain are both strong: 6,610/mo searches (99.8% transactional, second-highest volume in the batch), 24/30 BURNING pain, and a 0.2-month payback. The problem is the bottom of the stack: Funding 1/10 COOL ($2M category total, the coldest in the entire cohort) and Barrier to Entry 12/24 TOUGH against entrenched event platforms Cvent, Bizzabo, Swapcard, Hubilo, plus the more on-thesis Vendelux and Lensmor (which already score exhibitors against ICP and automate event-to-pipeline outreach). The pain quotes are about CRM friction and Cvent alternatives ("Do you know any alternative to CVENT," "the learning curve of any CRM is hardest to adopt"), which is buyer dissatisfaction Pavoot can exploit but also a crowded switching market. A single quoted price of $7,552/mo with $243-810 CAC implies a fast-payback SMB motion, but the COOL funding says investors do not believe events-to-pipeline is venture-scale.

What it does. An AI platform that takes a founder from idea to launched business, validation, product, payments, incorporation, and launch marketing, in one workflow.

The public-data read. The strongest pillar stack in the batch on paper: Demand 30/35, Monetization a perfect 20/20, BURNING pain, and 9/10 budget proof, with 2,790 searches/mo at 95.6% transactional intent. But it also carries a TOUGH competition score (12/24), because "idea to launch" means competing simultaneously with Stripe, LegalZoom, Shopify, Bubble, Replit, and Deel, each of whom owns one slice deeply. The pain quotes are sharp and specific, the entire LLC-formation thread (LegalZoom "rip off," "always upselling," r/llc), which is a real, narrow wedge inside a sprawling promise. Economics look fine ($96-180/yr ARPU, 3.3-month payback, CAC $366-1,220) but the SaaS path carries a scary 28% annual churn, the signature risk of "do-everything" founder tools.

What it does. Autonomous end-to-end customer-ops platform (first sales call through onboarding, support, success, expansion) aimed at AI-native startups.

The public-data read. Demand is lukewarm at 820 searches/mo, 40% transactional, KD median 20, but social pain is BURNING (24/30, 36 mentions) across r/CustomerSuccess, r/Zendesk and r/AI_Customer_Support, so the pain is real even if the search head is thin. The problem is the incumbent wall: 10 direct competitors led by Sierra, Decagon, Kore.ai, Cognigy, Intercom and Zendesk, with Zendesk publishing Robinhood/Brink case studies and Intercom citing Ramp/Notion as the exact AI-native buyer Akkari wants. Monetization reads STRONG ($132/mo headline but real plans $1,000-$8,000/mo + usage) yet the estimated payback is 58.4 months on a $1,423-$4,742 CAC, which means this only works at the enterprise ARPU ($24K-$120K), not self-serve.

What it does. AI voice agents plus guest intelligence that automate restaurant operations from call handling to table management.

The public-data read. Pain is BURNING (25/30, High evidence) but the headline demand is the structural problem: 70 searches/mo (LUKEWARM 21/35) on 99.6% transactional intent, KD 13, $15.21 CPC — real buying signal on a near-empty pool, so SEO won't validate this. It walks into SoundHound AI (QSR voice infra), SevenRooms, Resy, Tablein, Eat App, Nory and Fourth, which is "crowded but doable" (14.4/24). The most on-vertical pain is the r/restaurant operator asking "where to put my marketing spend and the ROI from that spend" — that's a budget-conscious operator, not someone screaming for voice AI; several of the other "top" quotes are voice-AI builders (r/LLMDevs, r/AI_Agents) talking about how hard real-time voice is, which is a build-risk signal, not demand. Monetization is STRONG (18/20) at a credible $159–599/mo against named peers, CAC $152–507, 1.2mo payback — believable for software. Funding is COOL (3.5/10): Nory has stacked $58.7M across three rounds in back-office restaurant ops without owning the voice layer, so the money is in the category but next to Elyra's wedge, not on it. Weakest signal is demand velocity — 70/mo means direct outbound, exactly what the founder's "21-day paid concierge pilot" next move concedes.

What it does. human backup for agents

The public-data read. Big search (9,055/mo, KD 64) but it is "AI customer service," dominated by Intercom, Sierra, Cresta and ASAPP. The killer signal is r/ExperiencedFounders, "An AI Agent Just Destroyed Our Production Data." CAC is brutal ($985-3,282, CPC $98).

What it does. A self-driving autonomous coding IDE that plans, edits, debugs and ships code with developer review.

The public-data read. Demand is the strongest pillar at WARM 29/35, 430 searches/mo, 100% transactional, KD median 25 and leading growth, and the payback is the healthiest among the coding plays at 30.8 months on a $341-$1,135 CAC. But this is the most brutally funded category here: $1.2B across 5 raises, with Cursor ($60M, a16z/OpenAI), Augment Code ($227M), Codeium ($150M), Magic ($320M) and Cognition ($400M) already shipping, plus GitHub Copilot, Claude Code, JetBrains Junie and Amazon Q Developer. Social pain is only CHRONIC 17/30, and the complaints (r/cursor "Cursor has been damn near unusable... massive slowdowns," r/ChatGPTCoding price gripes) are about existing tools' reliability, not an unmet need.

What it does. AI that automatically sends personalized physical gifts to prospects to book meetings and drive referrals.

The public-data read. Pain is BURNING (25/30, 39 mentions, "Frustrated") across r/b2b_sales, r/CRM, r/ExecutiveAssistants and r/automation, and purchase intent is HIGH at 97.6%, though volume is a thin 660/mo. The standout pain is the r/automation thread "HALO has been frustrating lately, so I started researching simpler automated gift-sending platforms" plus the r/CRM "would you spend $20k on gift cards, trade shows" question, both showing budget and switching intent. But the category is owned: Sendoso, Reachdesk, Postal, Alyce, PFL and Goody, with Reachdesk already marketing "AI-powered gifting... track revenue influence in CRM," which is precisely Archer's pitch. The funding pillar is COOL (1/10): Sendoso raised $100M in Sep 2021 (SoftBank) and Reachdesk $43M the same month, then the category went quiet for ~4 years.

What it does. Certification, financial guarantees, and liability insurance for autonomous AI agents.

The public-data read. This is the most speculative bet in the batch - genuinely novel but very early: 50 searches/mo, only 8% transactional intent, KD 5, a sharply negative trend (-0.73), and a demand score of 21/35 tagged COLD, even as social-pain (25/30) and monetization (20/20) score high. The competitor list is a mismatch that reveals the problem: ElevenLabs, Cognigy, NiCE, Zywave, and Salesforce are AI-agent and insurance-workflow vendors, not AI-agent insurers - the one genuinely relevant comparable (ElevenLabs' AIUC-1-backed policy for AI voice agents) appears as a feature buried inside a competitor, which suggests the category does not yet really exist. The most on-topic pain is the r/AI_Agents thread on needing to authenticate, authorize, and log AI agents in enterprise - a security/governance pain that is real but is a step short of "buy insurance for my agent." The scraped $990/mo price plus 10/10 budget-proof suggests serious willingness to pay if the need crystallizes. Category capital here is actually the most legible and on-point signal: Armilla AI ($25M Series A, "AI liability coverage," rel=1.0) is a direct competitor that has already raised real money, and FurtherAI/Avallon/Corgi cluster around AI-insurance - so the category is forming and funded, with Klaimee a fast-follower, not a first mover despite its "first-mover" claim.

What it does. AI servicing infrastructure for factoring and commercial lenders that automates invoice verification, reconciliation, and collections.

The public-data read. This has the cleanest demand signal in the lending set - 130 searches/mo, an exceptional 88% transactional intent, KD 8 (wide open), and the dossier flags "search velocity shows active demand + intent" as the top constraint rather than a weakness. The competitors are infrastructure incumbents - LoanPro, TurnKey Lender, and M2P Fintech - who already do servicing, billing, and collections automation, so Zolvo's wedge has to be the factoring/invoice-verification niche specifically. The most on-topic pain is the r/automation thread asking whether anyone has "successfully automated invoice or PO processing without having to build rigid templates," which is exactly Zolvo's job and a strong signal the manual pain is real. Budget-proof is 9/10 and the buyers (commercial lenders, factoring companies) clearly have wallets. Category capital is genuinely supportive and on-topic here: Growfin ($8M), Tesorio ($17M), Receeve ($16M debt-recovery), Billie ($30M) and Finally ($95M) are all plausibly adjacent AR/collections/lending companies, signaling real category money - though most are AR-collections tools, not factoring-servicing, so the precise niche is less crowded than the funding list implies.

What it does. end-to-end campaign agents

The public-data read. 2,830/mo but intent LOW (8%), into ActiveCampaign, HubSpot, Salesforce and Braze, with a TCPA shadow over AI marketing. Pain quote is an SMB comparing platforms (switching-curious).

What it does. phone numbers for agents

The public-data read. 3,350/mo, 68% transactional, into Twilio plus the voice-agent wave (Vapi, Retell, Bland). The worst CAC in the batch ($1,056-3,521, CPC $106).

What it does. AI-native investment research platform that proposes portfolio-grounded trade ideas for hedge funds, family offices, and RIAs.

The public-data read. Demand is moderate but qualified: 690 searches/mo at a healthy 57% transactional intent and KD 33, selling to a high-value buyer (funds, family offices, RIAs) where the price field is N/A but willingness-to-pay in this segment is well established. The competitive wall is the story: Hebbia, AlphaSense, and FactSet are entrenched, deep-pocketed incumbents, and LinqAlpha is a near-identical "multi-agent investment research for hedge funds" pitch already in market, so Kimpton is entering a knife fight, not an empty room. The most on-topic pain quote is the Quora "What are some alternatives to Bloomberg terminals?" thread, which confirms appetite to escape incumbent pricing but also that the comparison set is Bloomberg/FactSet, a brutal anchor; note that two of the four pain quotes (a C printf bug, an IT asset-management thread) are off-topic noise, so the social-pain score is thinner than 39 mentions suggests. Category capital is only partly legible: Finster AI ($15M series A, "AI fintech research") is a plausible comp, but Saturn, Paygentic, and Natural are advisory/payments-adjacent and read as off-category, so competition is real but the funding picture is hard to read cleanly from public data. The unscored layer is lighter here than for the execution plays (research/recommendation, not custody), but proposing "trades" to regulated funds still raises investment-advice and data-licensing questions that the score ignores.

What it does. Water intelligence that helps commercial and residential property operators detect leaks early.

The public-data read. This is a hardware-flavored play where the public-data lens visibly under-rates the atoms: demand is 300/mo but only 8% transactional (WARM 21/35, mostly researchers), and the "0.3-month payback" on a $61–202 CAC is implausibly short for anything that requires installing sensors and shutoff valves on a property — treat that as a SaaS-only artifact that ignores hardware cost and install friction. The competitor wall is consumer/prosumer hardware: FloLogic, Phyn, StreamLabs, Flo by Moen, Flume, Rheem — the named "AquaGuard Pro" portfolio player is the only one pointed at the commercial-portfolio buyer the founder wants. Pain is CHRONIC 21/30 but High-evidence and switching-shaped: the r/homeassistant "Moen Flo vs StreamLabs vs MCS Meter" comparison ("No real leak detection unless programmed… needs advanced programming and lots of testing") shows buyers actively dissatisfied and shopping. Funding is the genuinely weak signal at NONE (0/10) — the lone record is Wint's $35M Series C from Aug 2023, a well-funded commercial-leak player that raised long ago and never broke out, which reads as a category that absorbed capital rather than a greenfield. Monetization is STRONG on paper but the headline price ($199–799 consumer to enterprise-quote) and CAC don't anchor a clean commercial-SaaS motion.

What it does. A no-setup, zero-config AI life assistant that handles everyday tasks instantly out of the box.

The public-data read. A "proceed" decision riding 16,530 searches/mo at 99.1% transactional intent and a 0.1-month payback. But that volume is a mirage: the competitor wall is ChatGPT, Gemini, Claude, plus Lindy, Reclaim, Motion, Superhuman and Saner, and the keyword "best personal ai assistant" (KD 9) is the most contested phrase in consumer AI. Social Pain is only 17/30 CHRONIC and Neutral, and the HN evidence is a parade of competing launches (Sova AI, Native AI, ZAI Shell), meaning the loudest voices are other founders building the same thing. Funding is 7/10 HOT (Kai $125M Jun 2026, Oro Labs $100M Jun 2026). The "no-setup" wedge is a UX claim, not a moat, against products users already pay OpenAI and Google for.

What it does. AI-native ITSM platform that automates IT service requests end-to-end with policy workflows and audit logs for mid-market B2B.

The public-data read. This one has the cleanest budget proof in the batch (10/10, ServiceNow named a 2025 Gartner Leader, plus Console/Serval/Ravenna validating AI-native ITSM) and HIGH intent (480/mo, 66.7% transactional, 0.1-month payback). The catch is Barrier to Entry at 10.8/24 TOUGH, the lowest in the cohort: this is a head-on fight with ServiceNow, Atlassian, Freshworks, Ivanti, Moveworks, plus fresh AI-natives Serval ($47M, just valued at $1B Sequoia-led), Atomicwork, and Rezolve. Social pain is only 17/30 CHRONIC and Neutral. The standout demand quote (r/ITManagers: "No ticket, no human. Is anyone using an AI ITSM tool that actually resolves things instead of just routing them?") is the whole thesis in one line, but the geo is UNKNOWN (0/5 countries with meaningful volume) and these are 4-7 month enterprise sales cycles at $18K-60K CAC.

What it does. AI session programming

The public-data read. 1,160/mo but intent LOW (8%) and urgency very low (3.1/10), a developer-philosophy product against Anthropic, Cursor and Aider. The pain quote literally asks "is this a widespread pain or just my bubble?"

What it does. Agentic AI that automates the clinical-trial lifecycle from protocol design to FDA submission.

The public-data read. The scores show the classic enterprise-healthcare shape: burning social pain (25/30) and strong monetization (18/20) sitting on near-zero discoverable demand - 15 searches/mo, KD 43, though intent reads 100% transactional, meaning the few who search are buyers. The competitor list is a wall of incumbents (IQVIA, Medidata, Veeva Systems, Saama, Clario), and the standout pain quote names them directly: an r/clinicalresearch user says "it's awful, i prefer medidata and medrio over veeva which is not user friendly," which is real switching frustration but also proof these systems are deeply embedded. Unlike most entries, the funding records here read as genuine category capital and validate the thesis: Grove AI ($5M seed, "agentic AI for clinical trial management," rel 0.98) and Triomics ($22M Series B + $15M Series A, oncology trial AI, rel 0.95) are direct, recent, well-vetted peers - this is a hot, contested category, not noise. That cuts both ways: Astraea is late to a space VCs are already funding, and the 4G Clinical $230M "later" round is the cautionary CATEGORY signal - large capital poured into trial-execution software that never produced a breakout, suggesting the category absorbs money without escaping incumbent gravity. The barrier the 6 signals cannot price: "automate to FDA submission" means an agent generating regulatory deliverables, where a single hallucinated endpoint or compliance miss is catastrophic - validation, auditability, and 21 CFR Part 11 compliance are the entire product, and that is a multi-year trust build.

What it does. AI-powered material takeoffs for concrete contractors.

The public-data read. A sharply narrow wedge with the best monetization in this tier (20/20 STRONG, $30–3,990/mo, 0.5mo payback) and BURNING pain (25/30), but the evidence quality is only Medium and the demand is thin: 55 searches/mo (LUKEWARM 24/35) at 100% transactional intent, KD 30, and a very high $37.83 CPC that signals real commercial value per click. The competitive set is dense and funded — Beam AI, Togal.AI, STACK, CountBricks, Kreo, Handoff AI, Autodesk Takeoff, PlanSwift — "crowded but doable" (14.4/24), with Autodesk's ecosystem the structural threat. Be candid that the social-pain mining badly misfired here: of six "top" quotes, four are Final Fantasy / JRPG boss-fight threads (r/FinalFantasy, r/FFVIIRemake) and one is an unrelated HN Zig thread — only the Quora takeoff-vs-estimate explainer is on-topic, so the 35-mention BURNING score rests on almost no genuine concrete-estimator pain and should be treated as low-confidence. Funding is HOT (7/10) but it's adjacent construction-tech (Attentive.ai $30.5M, Buildots $60M, XBuild $19M Jan 2026), not concrete-takeoff specifically — a category signal that capital is in construction AI, not proof of this wedge. The CAC of $378–1,261 implies an outbound sales motion, not the SEO-led path the score assumes, on a 55/mo search pool.

What it does. AI-native platform for wealth managers that captures client signals, reconstructs households and automates advisor workflows.

The public-data read. This is the only project scoring FAVORABLE on Barrier/Comp (20.4/24) - notably because the dossier found just 3 named competitors, not 10 - paired with 450 searches/mo at 8% intent (KD 14, easy) and a strong CHRONIC pain pillar; but Funding is a flat 0.0/10 (NONE) and the one funding record, Range's $28M Series B for AI-powered wealthtech (rel 0.92), is the rare on-category signal worth heeding. The named incumbents are formidable and embedded: Advisor360°, Envestnet, Addepar, Orion and InvestCloud already own the advisor desktop, data aggregation and reporting. The best pain quote is the r/CFP "tech stack deep dive" where an advisor breaks down "cost, how essential it is... and whether we're considering replacing it" - this is gold, an advisor actively auditing which tools to swap, the exact replacement moment Wealor needs. Budget-proof is 9/10 with a $1-3000/mo band. The regulatory reality is lighter than the trading projects but not zero: capturing client signals and reconstructing households touches RIA/broker-dealer data-privacy, Reg S-P and recordkeeping obligations, so the compliance bar is about data handling, not licensing to trade.

What it does. Autonomous AI that analyzes funnels, designs pages, and runs A/B tests for SMBs without manual intervention.

The public-data read. 19,020 searches/mo at 94.4% transactional and KD 40 is genuinely warm intent, but this is a fortress: Optimizely, VWO, Kameleoon, Dynamic Yield, AB Tasty, and Adobe Target already publish case studies (Canva +20%, Sephora +18%, Trello +15%) for exactly this "self-running optimizer" pitch. At $495/mo with a $330-$1,098 CAC and a claimed 1.8 month payback the math closes fast, but the social pain is thin and generic. The sharpest real CRO complaint, on r/conversionrate, asks for tools that "fix revenue leaks faster" and "make client reporting less painful," which sounds like an agency-reporting wedge, not autonomous page design.

What it does. Turns a business's intent into a built-to-order AI product embedded in the team's existing workflows, sold mostly to SMBs.

The public-data read. Search is a thin 1,100/mo at just 14.1% transactional and KD 24, so this is not a keyword-discovery business, yet social pain reads BURNING (25/30, 31 mentions across r/n8n, r/msp, r/automation, Hacker News). The competitor wall is real and branded: Zapier, Workato, n8n, Microsoft Copilot Studio, Relevance AI, Lindy, plus Sierra and Moveworks on the customer-proof side. Monetization is the strength (20/20, $10-$8,000/mo, est. CAC $242-806, ~2.6mo payback), but the catch is that "built-to-order AI" is the most copied pitch of 2026 and the services path that pays best (deal cycles 30-90 days, 22% churn) is the one that doesn't scale.

What it does. AI governance as a managed service that monitors every clinical AI model in a hospital for drift, fairness, and safety.

The public-data read. This is the most defensibly-timed idea in the group: 655 searches/mo at 99% transactional intent with low KD (7), riding the regulatory wave of hospitals being forced to govern deployed AI. It is also explicitly the most crowded ("CROWDED BUT DOABLE," Barrier/Comp 14.4/24). Named competitors split into two camps: clinical-AI vendors Aidoc and Viz.ai (who monitor their own models) and horizontal MLOps governance player Fiddler AI (drift/bias/explainability) - the risk is being squeezed between them. The best quote is a genuine buyer-pain cry from r/HealthTech: "I'm stuck a bit with a healthcare AI integration problem and genuinely don't know if I'm missing something... We need to integrate" - integration friction is exactly the wedge for a monitoring layer. Budget-proof is 9/10 but the scraped price ($1-$60/mo) looks mismatched to an enterprise hospital managed-service sale, so pricing is unclear. Category capital is thin and hard to read: Fairly AI ($2M pre-seed, AI risk/governance, rel=0.96) is the only clean comp, while the OpenEvidence and Pave records are noise - so competition/capital cannot be reliably sized from public data here.

What it does. cloned best recruiters

The public-data read. 1,470/mo, 99% transactional, KD 64 (hard), into Paradox, HireVue and Fetcher. Urgency very low (2.3) and CAC brutal ($1,027-3,424, CPC $103).

What it does. always-on AI analyst

The public-data read. 800/mo, intent LOW (8%), payment signal NONE, into ThoughtSpot, Domo, Tableau and PowerBI. r/dataanalysis fears the role becoming obsolete (cultural, not buying).

What it does. sandboxes for agents

The public-data read. 100/mo, intent LOW (8%), overlaps Runtime in this batch plus E2B, Modal, Northflank and Docker. Senator Cruz's "AI sandbox" headline is a regulatory pun, not a tailwind.

What it does. An AI-run research lab that automates research workflows for SMBs and founders.

The public-data read. This is the most mispositioned idea in the batch. Demand is 330/mo with only 8% transactional purchase intent and a brutal KD median of 71, and the "competitors" are literally frontier labs: DeepMind, AI2, OpenAI, Anthropic, Cohere, Mistral and Cognizant AI Lab. Funding scores 10/10 HOT ($3.7B category, Thinking Machines Lab $2.0B, AMI Labs $1.0B, Humans& $480M), but that capital is flowing to foundation-model labs, not an SMB research SaaS, so the "validation" is a mirage. Social pain is only CHRONIC 17/30 and the most telling signal is the r/MachineLearning thread "Has 'AI research lab' become completely meaningless," which questions the category's coherence. Monetization at $200/mo with a 2.2-month payback looks clean, but selling a $200 "research lab" against names like DeepMind is a positioning problem, not a pricing one.

What it does. Builds verifier-grounded training data with frontier-model teams to push model capabilities.

The public-data read. First, a tagging caveat the data lens got wrong: PerfectBit is an AI training-data company, but it's filed under "Space & Frontier Tech" with a space-themed funding record (Fleet Space $100M) and space-mission "founder wedges" that don't match what it does — so the funding (NONE, 0/10) and wedge fields are mis-mapped and low-confidence; read them skeptically. The real competitive set is the brutal one: Scale AI, Labelbox, Surge AI, Toloka, Appen, Snorkel AI, Encord — all funded, entrenched data vendors (CROWDED BUT DOABLE 13.2/24). Demand is WARM (19/35), 100/mo searches at 87.5% transactional, KD 21, with a low $2.69 CPC suggesting little commercial competition on the term. The social-pain mining also misfired: the "top" quotes are E2E/integration-testing Indie Hackers posts and unrelated HN threads (HLS, OpenSign, Home Assistant), none about RLHF/verifier data demand — so CHRONIC 20/30 at Annoyed intensity rests on off-target evidence. The genuine wedge — "verifier-grounded" data, i.e. RL/verification-reward data rather than generic labeling — is a real 2026-native angle Scale/Surge don't natively own, but it's selling into a handful of frontier labs, which is a tiny, relationship-gated buyer set, not a search-led market. Monetization reads STRONG ($1–5,000/mo, $27–90 CAC, 1.0mo payback) but those are self-serve numbers that don't fit a frontier-lab enterprise sale.

What it does. idea-to-explainer video

The public-data read. 190/mo but urgency very low (1.6/10), and Google just "got into the whiteboard business" while Vyond, Animaker, Powtoon and HeyGen own explainer video.

What it does. warehouse camera vision

The public-data read. Near-zero search (10/mo) but a concrete, expensive problem (pallet/parcel dimensioning) with installed competitors (vMeasure, Basler, Zivid) selling $4k-25k+ systems. "Use existing cameras, no new hardware" is the real wedge.

What it does. Builds robots and software for farm automation.

The public-data read. This is the clearest case in the tier of the public-data lens under-rating atoms: monetization scores STRONG (17/20) with a 0.1-month payback on a $35–117 CAC, which is absurd for a company whose own price anchor is "$18,000 entry-level to $200,000+ advanced AI systems" — the CAC/payback fields are a SaaS artifact and should be ignored for a capital-heavy ag-robotics build. Demand is WARM (25/35) but on just 40 searches/mo at 100% transactional intent (KD unscored), and competition is genuinely TOUGH (10.8/24) against Carbon Robotics (laser weeding), Verdant, FarmWise, Naïo, Aigen and Bonsai. Pain is the weakest pillar — CHRONIC 17/30 at Neutral intensity, Medium evidence — and the mining is badly off: the "top" quotes are HN macro-economics/Fed arguments and a ChatGPT-bias thread; the only relevant signals are the r/robotics "robotics industry is dead, a bad choice for jobs" thread and an r/BEEPTOOLKIT FarmBot critique about "difficult integration with external devices" — neither is a farmer in buying pain. Funding is COOL (3.5/10) but the comps are real and large (Carbon $70M Series D, 4AG $29M, 80 Acres $115M) — capital is in ag-robotics, but it has pooled around specific outcomes (laser weeding, vertical farms), which is the lesson: undifferentiated "farm automation" is the trap, a single-crop ROI wedge is the path.

What it does. Creator-first platform to generate AI video/image content and monetize it via subscriptions, fan funding, and a marketplace.

The public-data read. Fluenta's engine rates this strong_build, but the read is more cautious: 1,250 searches/mo at 100% transactional and BURNING 25/30 pain, yet KD 64 (hard to rank) and the competitors are funded video-model heavyweights (Runway, Pika, Luma, Kling, OpenArt, Pixverse, Hailuo), so this can't win on generation, only on distribution and payment rails. The pain is real but two-faced: r/StableDiffusion ("monetizing AI art is hard... many are strongly opposed to AI") and r/rpg show monetization friction AND active hostility to AI art, a demand-side headwind. Pricing $7-$300/mo with a 19.3 month payback is rough; the file's own models cluster at $9.99/mo with weak LTV ($120-$238).

What it does. low-cost AI compute

The public-data read. Huge search (62,830/mo, KD 71) but it is the GPU-cloud knife fight (RunPod, Vast, Lambda, CoreWeave, NVIDIA), capital-intensive and race-to-the-bottom on price. "Cheapest across providers" is thin-margin arbitrage.

What it does. Turns chaotic purchase orders from metal-finishing shops into ERP-ready data with human-in-the-loop exception handling.

The public-data read. The most legitimately differentiated entry here: a BURNING 25/30 pain score, 100% transactional intent (180 searches/mo, KD 15), and a razor-narrow vertical wedge. Competitors are real but mostly horizontal PO-automation (Workist, Canals AI, WizCommerce, Orderful) plus Steelhead in the metal-finishing ERP lane specifically. Monetization is strong: $99-$399/mo, a tiny $27-$90 CAC, 0.3 month payback. The catch is medium evidence confidence and a pain corpus polluted by off-topic Linux/aviation threads; the on-target r/Netsuite quote ("processing orders like it's 1999") is the real signal. Category funding is HOT ($225M, Oro Labs $100M + Kai $125M Jan 2025).

What it does. AI agents that automate quoting, purchase orders, and supplier communication for manufacturers.

The public-data read. The best demand profile in this tier — WARM 26/35, 230 searches/mo at 100% transactional intent, KD 20 — and a very high $71.00 CPC that screams real budget per click. But it's a head-on procurement fight: Arkestro, Precoro, Tradogram, Coupa, Ivalua and SAP Ariba (CROWDED BUT DOABLE 14.4/24), where Coupa/Ariba own the enterprise system of record. The most useful pain quote is the Indie Hackers note that "most SMB suppliers do not have IT teams to build those integrations… they need something that connects without a six-month implementation" — a real wedge against enterprise source-to-pay — but pain overall is only CHRONIC 21/30 at Neutral intensity on Medium evidence, and another "top" quote is an AI-agent builder warning "an AI agent automates the wrong logic… that is operational risk," which cuts against trusting agents with POs. Monetization is STRONG (17/20, $225–999/mo vs. named peers, 2.6mo payback) but the CAC is heavy at $710–2,367, demanding an outbound motion despite the "SEO-led survivable" framing. Funding is COOL (3.5/10): the comps are agent-infra (Relevance AI $24M, Stack AI $16M, both May 2025), not procurement breakouts — capital is in the agent layer, not proven in manufacturing procurement. Note the dossier has no founder wedges and a notably thin "next move," so the segment focus is undefined.

What it does. A deterministic AI model for developer tasks — OCR, scraping, classification, speech-to-text and web search — built to return predictable, reliable outputs in production instead of the variance of a general LLM.

The public-data read. On paper this is one of the strongest demand profiles in the batch: 34/35 on demand against ~1.85M searches/mo, 100% transactional intent, a median KD of 9, and a market the model reads as under-served, with monetization a perfect 20/20 (SaaS, $300–$350,000/mo, budget proof 10/10 and an estimated payback of 0.1 months). The catch is the pain pillar at 3/25: social pain is labeled BURNING (25/30, 33 mentions) but the buyer-weighted cut is only 2.3/30 — the complaints are mostly suppliers building OCR and scraping tools, not buyers bleeding from flaky outputs, so the pain reads inflated. The competitor wall is the heaviest kind: 10 direct competitors that are the cloud primitives and the model labs themselves — AWS Textract, Google Cloud Vision, AssemblyAI, Deepgram and Diffbot, plus OpenAI, Anthropic and Cohere. Capital is hot (funding momentum 8.5/10, $725M across three recent raises including Replit's $400M), and Fluenta's own verdict is strong_build at high confidence — but the whole thing hinges on positioning: "predictable AI for developers" is broad, and the 1.85M searches are head terms (98.7% US) like "developer tools platform," not one sharp, expensive workflow failure a team will rip out a vendor to fix.

What it does. Wearable that reads your emotions to help you understand and improve your interactions.

The public-data read. The tag (Fitness & Wearables) is a loose fit; this is an emotion-AI / "EQ" wearable, not a fitness/recovery band. Demand is lukewarm-to-real: 1,460 searches/mo at 40% transactional intent (KD 45), the best intent/volume combination among the consumer plays here, but the trend is flat and geo is thin. The competitor set the dossier names is almost entirely emotion-AI software, not wearables: Affectiva, Realeyes, Hume AI, Cogito and Sentiance are emotion-recognition engines, which signals the hard part (reading emotion accurately) is a software race Anoria would have to win against specialists, while the funding records point to the real wearable bar - Oura's $100M and Whoop's $200M show what it costs to win a consumer band, and Affectiva's $12M is on-category emotion-AI. The most honest pain quote is the r/apple wearable-fatigue note that the killer flaw was "the 1-way nature... I could see notifications but to do anything with them I [had to take out my phone]" - a warning that single-purpose wearables get abandoned. The Quora quote even concedes the AI "shall not be as accurate as you wish" early on, which is the whole product risk in one line. Budget-proof is 9/10 at a $99/mo price. No trading/licensing exposure here, but there is a real privacy/consent surface in continuously inferring a wearer's (and bystanders') emotional state.

What it does. Specialty insurance company placing hard-to-place commercial E&S risks with fast turnaround and named broker access.

The public-data read. This is not a software bet, it is an insurance distribution/carrier bet, which changes everything about how to read it. Demand looks healthy on paper - 870 searches/mo, KD 15, budget-proof 9/10 - but intent is only 38% transactional and the trend is negative (-0.45), and the 25/35 demand score is tagged LUKEWARM. The competitors are an existential problem for a startup: Ryan Specialty, AIG Lexington, Burns & Wilcox, Amwins, and RT Specialty are the entrenched wholesale/E&S giants whose entire moat is carrier relationships and broker access - the exact "exclusive broker access" Hedge claims as its edge. The most on-topic pain is the r/InsuranceProfessional underwriter saying "carriers are painfully slow to give quotes... 2 weeks... give at minimum 30 days," which validates the speed wedge precisely. Category capital is real and on-topic: Corgi ($108M), Nirvana ($100M Series D), WithCoverage ($42M), and Sixfold ($30M) are all AI-native hard-to-place/E&S insurers, so the category is extremely well-funded - which is as much a threat as a validation. The hard truth the 6-signal score ignores: as a "specialty insurance company," Hedge needs MGA/carrier or surplus-lines broker licensing, capacity from reinsurers, and surplus-lines compliance in every state - this is a balance-sheet and regulatory build, not a PLG SaaS, and the "PLG / self-serve" channel tag is therefore nonsensical for this business.

What it does. AI agents for property management.

The public-data read. Monetization is maxed (20/20 STRONG, $50–3,990/mo, 3.1mo payback — an honest payback for once) and funding is HOT (7/10), but the demand is the soft spot: LUKEWARM 20/35, 260 searches/mo at only 8% transactional intent (mostly researchers), KD 9, with a high $38.47 CPC. The "AI agents for property management" one-liner walks straight into EliseAI (deep multifamily leasing automation, and a direct funded peer at $75M), Super (virtual receptionist), AppFolio, Yardi, Entrata, RealPage and Buildium — incumbents that own the PMS system of record and can bundle agents into existing seats. Pain is CHRONIC 20/30 at Neutral on Medium evidence, and the mining is off-vertical: the "top" quotes are a hotel PMS/channel-manager Quora post and unrelated HN threads (an OS-vs-app argument, a holiday-park PMS "Show HN," a Wayland gripe) — none is a property manager in buying pain. The funding wall is the real category tell: EliseAI $75M, Guesty $130M, Vantaca $300M (Oct 2025), Juniper Square $130M, Buena $49M — enormous capital already in proptech ops, much of it pointed at exactly this workflow, so the honest read is a well-funded, incumbent-heavy category, not white space. The founder's own conclusion concedes weak search + low intent mean SEO won't validate it.

What it does. cloud Xcode for agents

The public-data read. Decent search (8,290/mo, 99% transactional) but it rides Apple ("remote Xcode/iOS simulators"), and Apple owns Xcode Cloud and the toolchain. r/iOSProgramming pain ("Xcode cloud build times ridiculous") is real.

What it does. team agent memory

The public-data read. 90/mo, the third memory play in this batch (mem0, Zep, Letta, Supermemory). Good payback (1.6 mo). Pain quote is generic ML.NET anomaly detection, off-target.

What it does. Provides novel preclinical and medical datasets plus causal inference to fine-tune and deploy healthcare AI models.

The public-data read. The data is contradictory in a telling way: demand is thin (15 searches/mo, KD 50, 40% transactional) yet this is the only entry with a perfect 20/20 monetization AND a 10/10 HOT funding pillar - meaning the model captures value well and capital is flowing, but almost nobody is searching for it, so growth will be sales-led against a small set of sophisticated buyers. The competitors are the serious real-world-data incumbents (Flatiron Health, Truveta, Nference, Aetion), which already aggregate de-identified records and sell regulatory-grade evidence, so BioStack's wedge has to be the "novel/proprietary" and "causal inference" angle rather than dataset breadth, where incumbents dominate. The sourced pain is weak and off-center - the closest real quote is a Quora student asking "I have to do a final year project on Data Mining for healthcare... I am finding it difficult to get a data set," which signals data scarcity but not enterprise buying pain. The funding records actually support the HOT pillar with plausible recent peers: Dandelion Health ($14M Series A, healthcare AI data/analytics, rel 0.93) and Enzo Health ($20M Series A, rel 0.88) are real category capital, while the Caring and Scarlet Therapeutics entries are noise - net, this is a genuinely funded, genuinely contested data-supply category. The barrier the score discounts: proprietary clinical datasets live or die on data provenance, de-identification compliance (HIPAA/IRB), and exclusivity of source agreements, and incumbents like Truveta and Flatiron already locked up large health-system data partnerships - the moat is who you signed, not your model.

What it does. async coding agents

The public-data read. 10/mo search, intent LOW, against the platforms themselves (Jules from Google, GitHub, Cursor, OpenAI). Honest skepticism on r/AI_Agents ("so-called async agents are really just long-running sync workflows"). Absurd 508-month payback.

What it does. Autonomous AI that helps SMBs start, run, and grow companies end-to-end, an always-on company-building assistant.

The public-data read. Fluenta's own engine flags this kill_broad, and rightly: 75 searches/mo, 8.0% transactional, UNKNOWN geo, and the competitors (Lindy, cofounder.ai, twin.so, Gumloop, Zapier, n8n, Make, Stack AI) are general agent-orchestration platforms that this can't out-horizontal. Funding is HOT (10/10, category $465M; Axiom Math $200M, Oro Labs $100M Jan 2026), which is a flashing "well-capitalized incumbents" warning, not an opening. Monetization is technically 20/20 ($10-$8,000/mo) but payback is 9.5 months and the pain corpus is mostly off-target (Palantir valuation, MongoDB outages). The honest meta-signal is the r/automation founder ("not sure if the opportunity is as big as some make it seem") and the HN "AI-native business" experiments, which read as hype, not jobs-to-be-done.

What it does. AI runs parallel employee interviews to capture tribal knowledge and turn it into a live operational map for mid-market B2B.

The public-data read. The budget proof is strong (10/10, with named manufacturing case studies: Tulip/Bosch, Augmentir/Lincoln Electric, Poka/Tesla, Guru/IBM) and intent is 100% transactional, but demand is tiny (140/mo, geo UNKNOWN) and the pain is diffuse: 21/30 CHRONIC, Neutral, with off-topic complaint quotes (interview anxiety, web archiving in Markdown) that suggest the scraper struggled to find people actually hurting over tribal-knowledge loss. The strongest real signals are an r/msp thread ("we're struggling with how scattered our troubleshooting info has become") and an HN founder noting Glean is "the pricey one aimed at big companies." The killer is the monetization math: stated price is only $100-250/mo, but Avg CPC is $101.9 driving CAC to $1,019-3,397 and payback to 15.8 months, by far the worst CAC-to-price ratio in the batch. Competitors (Skan, Poka, Tulip, Augmentir, Guru, WorkRamp) are mostly manufacturing connected-worker platforms, not the horizontal mid-market B2B tool Ontora describes.

What it does. AI back office for collision-repair shops that handles supplier calls, insurance paperwork, and record updates.

The public-data read. The most defensible wedge in this tier: BURNING pain (25/30, High evidence) on 720 searches/mo at 100% transactional intent with a remarkably low KD 4 — meaning this is rankable, unlike most of the cohort. Competition is TOUGH (12/24) but the named set — Tekmetric, Mitchell, Solera, CCC Intelligent Solutions, AutoPoint, Audatex — are broad shop-management/estimating platforms and insurer-data giants, not back-office automation specialists, so there's a genuine gap. The pain quotes are real and shop-native: r/AutoShopOwners ("I love tekmetric and shopware but they offer more than I need… one man mobile operation"), r/Autobody shop owners giving feedback on estimating software, and r/mechanics asking for "free or affordable software… for a one man shop" — these are operators who find incumbents too heavy, which is exactly Parrot's lane. Monetization is STRONG (16/20, $1–439/mo vs. Tekmetric, 2.3mo payback) with CAC $204–679 — believable for a software back office. Weakest signal is funding (NONE, 0/10): the only comps are auto-AI infra (Kinetic Automation $21M, Helm.ai $31M), so there's no proof capital has flowed into collision back-office specifically — white space or unproven appetite. The CCC/Mitchell insurer-data lock-in is the structural risk, since insurance paperwork runs through their rails.

What it does. mobile runtime protection

The public-data read. 25/mo but KD 53, into Appdome, Promon, Digital.ai and Doverunner, mature mobile-RASP vendors. The Beijing security-software headline is noise for your buyer.

What it does. Provides robotic workers that staff warehouses.

The public-data read. The standout is the headline 12,370 searches/mo — by far the largest demand pool in this tier — but it's a trap: only 8% transactional (LUKEWARM 27/35), KD 10, $38.73 CPC, i.e. a huge generic "warehouse automation" research term, not buyers. The monetization line is the loudest tell that public data under-rates atoms: a $29/mo price (pulled from canvas.io) against a 72.3-month payback and $387–1,291 CAC — that is the worst payback in the tier and obviously wrong for warehouse robots that sell as RaaS at five-to-six figures; the $29 SaaS anchor is a mismatch and the whole monetization read is unreliable. Competition is genuinely TOUGH (9.6/24) against a wall of funded, deployed players — Locus Robotics, Geek+, Symbotic, Exotec, AutoStore, inVia, 6 River, Berkshire Grey. Pain is the weakest pillar (CHRONIC 17/30, Neutral, Medium evidence) and the mining is off: the "top" quotes are a r/robotics career-advice thread and HN posts on ROS2 frustration, GPIO, and robotics cost — engineering gripes, not warehouse operators in buying pain. Funding is HOT (10/10) but it's the category tell, not a tailwind: Sereact $110M, Pudu $150M, Fortem $25M, UVify $42M, NODA $25M — all 2026, all pouring into robotics, meaning InLoop would be raising into a richly funded, incumbent-dense field where capital is the table stakes, not the edge. The dossier lists no founder wedge and a vague next move.

What it does. An autonomous AI quant that runs investment research all the way through to executing live trades.

The public-data read. The headline demand (2,060 searches/mo) is misleading because purchase intent is only 8% transactional, meaning the searches are mostly curiosity ("can AI trade the markets?") rather than buyers, and that intent gap is the real signal here. The competitor set spans true heavyweights (WorldQuant, Numerai) and infra (Alpaca, QuantConnect), so KelAI is squeezed between firms that already run autonomous systematic strategies and the API/backtesting rails a sophisticated user would self-assemble. The most on-point pain quote, from r/Daytrading, captures the skepticism directly: "most still need a human to confirm orders. Has anyone actually removed themselves from the process completely?" which is both the wedge and the warning, because the honest answer in the threads is no. Budget-proof is 9/10 and the price band runs to $4,800/mo, but the category capital is hard to read as a competitive threat: the records (Rogo, Daloopa) are research-and-data tools, not autonomous-execution funds, and Numerai's $25M is a crowdsourced-model hedge fund, a different model entirely, so public capital says "research AI is funded" not "autonomous trade execution is winning." The unscored regulator looms largest: executing trades for others implicates broker-dealer/RIA registration, SEC/FINRA oversight, and custody rules, and "fully autonomous" execution is exactly what regulators scrutinize.

What it does. A Mac-native, screen-aware AI buddy that watches your screen and takes voice commands to finish desktop tasks in-flow.

The public-data read. 670 searches/mo with only 8% transactional intent and a median KD of 12 is a thin, low-purchase-intent top of funnel sitting underneath Apple Intelligence, Microsoft Copilot, Raycast Pro, and Rewind. Social Pain scores 25/30 BURNING across r/MacOS, r/macapps, and r/ProductivityApps, but the loudest quotes ("I'm looking for a list app with intuitive voice commands," r/productivity) are feature wishes, not budget commitments. Monetization looks clean on paper ($15-204/mo, payback 2.6 months, CAC $105-350), yet the only direct startup peer, Littlebird (raised $11M Mar 2026), is doing the identical "AI that watches your screen" pitch. The 8% intent number, not the BURNING pain, is the tell.

What it does. reclaim wasted GPUs

The public-data read. 10/mo, intent LOW, into NVIDIA, CoreWeave, Vast and Rescale, and Vast already runs an idle-GPU marketplace. The r/MachineLearning insight ("idle GPUs just sitting there") is real. Flat $50,000/mo pricing is odd.

What it does. agent web navigation

The public-data read. 80/mo in a hot, crowded lane (Firecrawl, Browserbase, Apify, Browse.ai), and Google "AI that takes over computers" is a platform threat. Pain quote shows devs already combining Firecrawl + Apify (solved).

What it does. A "self-driving brain" that autonomously monitors, decides, and executes enterprise operations workflows.

The public-data read. 90 searches/mo (but 56.2% transactional, KD 13) against Pega, ServiceNow, UiPath, Automation Anywhere, Celonis and Appian, a wall of entrenched enterprise automation incumbents. Funding scores 1/10 COOL with the comps dated to 2020 (Postman $150M, Notion $50M, Front $59M), meaning capital left this exact "autonomous ops" framing years ago. The killer is the monetization math: $25/mo headline price but a 14.1-month payback and CAC of $130-432, while the consulting+tooling model assumes $120k-250k ARPU. That is a $25 SaaS marketed against a six-figure enterprise sale. Social Pain is only 17/30 CHRONIC and Neutral, with complaints drifting into self-driving cars and airline pilots rather than ops software.

What it does. AI customs brokerage that automates regulation research and entry filing for SMB importers.

The public-data read. The sector tag (Wealthtech & Personal Finance) is wrong; this is TradeTech / customs brokerage. The demand picture is almost invisible (10 searches/mo, KD None) but with 47% transactional intent and a $3,586/mo scraped price, the few people searching are buyers, not browsers. The named competitors are credible and entrenched: AI-native challengers Digicust, iCustoms and Anker, plus the giants Descartes Systems Group and Livingston International who already own importer relationships. The sharpest on-topic pain is the r/CustomsBroker request for "a platform that offers strong automation capabilities, supports applicable tariff stacking, includes compliance tools like dashboards," which is exactly the buyer Alchemize wants and exactly the buyer the incumbents already serve. Budget-proof is 9/10. On capital, the funding records are mostly noise (Higgsfield AI video, Emergent app-builder, Volante bank payments are not customs competitors); only OnePort 365's $5M seed for freight/customs digitization is plausibly on-category, so competition and capital are hard to read cleanly from public data. The unscored reality is licensing: filing customs entries in the US requires a licensed customs broker and a CBP/ACE filer relationship, so Alchemize is selling into a regulated profession, not disrupting it freely.

What it does. An operating system for laboratories covering protocol validation, experiment preview, lab ordering, and data analysis.

The public-data read. Search looks healthier at 1050/mo but intent collapses to 8% transactional and the trend is steeply negative, so most of that volume is informational, not buyers - the sector tag "Healthcare & Digital Health" is also slightly off, since this is really research/biotech LIMS, not clinical care. Named competitors are the established LIMS/informatics stack: LabWare, LabVantage, Clinisys, Benchling, and Sapio Sciences, all of which already do sample tracking and ELN/LIMS. The only sourced pain quote is weak and old (r/sysadmin on LIMS storing multiple orders and EMR integration), which undercuts the "BURNING" social-pain label. The scraped price note shows enterprise reality - $10k-$50k for small implementations up to $100k-$1M+ - which means budget exists but so does a long procurement cycle. Category capital is partly legible: Elea AI ($4M seed, pathology labs, rel=0.95) is a plausible adjacent player, while the OpenEvidence series (A/B/C) records are clinical-search noise, not lab-OS competitors.

What it does. AI "deal-advancing agents" that act across CRM, calls, and Slack to push stalled deals forward so nothing slips through the pipeline.

The public-data read. Demand is LUKEWARM and weak, 260 searches/mo at only 8% transactional intent, KD 25, so search is a slow, competitor-heavy path against Salesloft, Outreach, Apollo, Gong, Clari, 11x, Artisan, and Conversica. Social pain is CHRONIC but Neutral (21/30) and the quoted threads are diffuse marketing-automation gripes, the one sharp signal is r/CRM ("workflow automation tools are breaking our CRM... over-triggering and unclear workflow ownership"), which is actually an argument against another autonomous agent. Monetization scores 19/20 yet the listed price range is $0-0/mo, a data gap that undercuts the score, with CAC $213-709 on a $21.26 CPC.

What it does. Enterprise-grade AI voice and chat agents that use customer data and policy rules to resolve support issues end to end.

The public-data read. This is the softest demand profile among the support plays: LUKEWARM 17/35, 1,630 searches/mo but only 8% transactional and lagging growth. Pain is CHRONIC 21/30 and genuinely "Frustrated," with strong evidence quality, the best quote being the r/customerexperience thread "when does automating customer support actually [help]" and the r/FedEx complaint "the AI bot fails to understand basic requests and repeatedly disconnects... the worst." Critically, the r/customerexperience thread "need honest feedback on Decagon, Sierra, Fin AI" shows buyers actively comparison-shopping the incumbents, not Cignara. The competitor wall is everyone at once: Intercom, Zendesk, Cognigy, Ada, Decagon, Sierra, PolyAI, Kore.ai. Funding is COOL (1.5/10, only GuruSup $1.4M). Monetization shows a clean 1.4-month payback on a tiny $35-$117 CAC, but the real plans are $2,000-$15,000/mo enterprise with 2-5 month deal cycles, so the SMB CAC math is fiction.

What it does. Builds AI-powered, low-cost autonomous counter-drone defense systems for the FPV-drone era.

The public-data read. A defense-hardware play where nearly every public-data signal is the wrong instrument for the category. Demand is LUKEWARM (19/35) at 20 searches/mo, 8% transactional, KD 19 — but counter-drone defense is sourced through direct relationships and procurement, not search, so low volume is expected and not disqualifying (the founder's own conclusion says exactly this). Monetization scores STRONG (19/20) with a 0.1-month payback on a $108–358 CAC, which is implausible against its own price anchor of "sub-$1,000 to $50,000 low-end, up to £125k–£2.5M+ military-grade" sold via enterprise/defense sales — the SaaS CAC/payback fields don't apply to a defense-hardware build. Competition is TOUGH (12/24) and the named set is the heavyweight defense primes: DroneShield, Dedrone by Axon, Anduril (Lattice), Epirus, BlueHalo, RTX, Rafael, IAI — credibility- and contract-gated incumbents. The genuinely on-topic pain is sharp and well-targeted: r/NonCredibleDefense and r/LessCredibleDefence threads on cost-vs-payload ("the problem is cost and payload… decreased payload leads to decreased effectiveness") and saturation ("drone defense systems… can be overwhelmed") — real doctrinal critiques of cheap C-UAS, though from defense enthusiasts, not procurement buyers. Funding is WARM (5.5/10) on a single but enormous data point: CHAOS Industries $510M Series D (Nov 2025) — capital is flooding C-UAS, which is both validation and a warning that well-funded primes are racing the same low-cost thesis.

What it does. synthetic customer research

The public-data read. 40/mo, intent LOW (11.6%), into SyntheticUsers, GetMinds, Ditto and Qualtrics. The validity question is existential: do "AI customer clones" produce research buyers trust?

What it does. AI voice agents that replace legacy phone menus for SMB support, sales and scheduling.

The public-data read. Demand looks healthy on paper: WARM 26/35, 3,470 searches/mo, 49.8% transactional, and an unusually low KD median of 2 ("automated customer service" KD 2 is genuinely rankable). But social pain is only CHRONIC 17/30, and the most credible signals are builder cautionary tales, not buyer demand: the Indie Hackers post "5 lessons from building a voice AI product nobody warned me about" (latency, silence detection) and the warning that a bot "mishearing 111-222-97 as 111-222-57 isn't a problem, it's a disaster." The category is brutally crowded with Retell AI, Poly.ai, Bland, Vapi, Synthflow, Cognigy, Cresta and Decagon, several of which are infra layers a new entrant would build on. Funding is COOL (3.5/10, only VoiceLine $10M). The payback estimate of 137.2 months on a $507-$1,689 CAC confirms this only works at vertical ACV, not the $20/mo floor.

What it does. Agentic workspace for R&D teams that accelerates literature review, methodology, analysis, grants, and drafting.

The public-data read. The Healthcare tag here looks misapplied - the product, competitors, and pain are all general scientific R&D tooling, not clinical/regulated healthcare, so the "compliance-aware founder / partnerships-first" framing inherited from the sector tag overstates the regulatory angle. Demand is very thin (10 searches/mo, KD unrecorded) though intent is a healthy 59% transactional, and the competitor field splits into two camps: heavy lab-data incumbents (Benchling, Labguru, LabArchives) and fast-moving AI research assistants (SciSpace, Elicit), meaning Enjamb is squeezed between sticky systems-of-record and free-to-cheap AI tools. The one genuinely on-topic pain quote is sharp and useful - r/labrats says "LabArchives is pure jank. It runs like crap... OneNote has problems but it's far superior" - real incumbent dissatisfaction Enjamb could exploit, but it points at lab-notebook UX, not literature/grant drafting. The funding records are real category capital and read clean: Elicit ($9M seed, rel 0.98), Hebbia ($30M Series A, rel 0.95), and Solve Intelligence ($12M, rel 0.92) are direct AI-research-acceleration peers, so this is a funded, contested space - but the funding pillar at 1.5/10 plus a broad "agentic workspace" scope suggests Enjamb is undifferentiated against tools that already each own one job. The real barrier (not regulatory, despite the tag) is focus and switching cost: R&D teams already live in Benchling or Elicit, and an all-in-one "workspace" must beat both at their own job to earn the switch.

What it does. Foundation models that score a biologic's manufacturability from day one to de-risk and speed up drug production.

The public-data read. This is a thin-demand, deep-moat play: only 50 searches/mo at 40% transactional intent and KD 13, so SEO will never carry it - the dossier's own top constraint flags content-and-partnership as the only route. The named competitors (Recursion, Insitro, Sana Biotechnology) are not SaaS sellers but capital-heavy AI-biotech platforms, which tells you the real game is winning pharma partnerships, not closing inbound. The strongest on-topic pain signal is a Quora thread asking about "drug candidates that were very promising from a biological perspective, but failed due to formulation or manufacturing problems" - genuine, but it is a research-curiosity question, not a buyer with budget. The 9/10 budget-proof and 19/20 monetization scores reflect that pharma will pay for de-risking, but the funding pillar is only 4.0/10 and the cleanest comparable, Quris ($9M seed, patient-on-a-chip), is a tiny round; the Sanofi Ventures $625M and Vida Health records are category noise, so competition/capital is hard to read from public data here. The unscored risk the 6 signals ignore: a "manufacturability model" is only as good as its validation against real CMC outcomes, and biologics teams will not trust a prediction without wet-lab proof, so the clinical/regulatory credibility bar gates adoption long before pricing does.

What it does. brand layer for agents

The public-data read. 460/mo into Jasper, Writer, Typeface and Brandwell, AI-brand-content tools that have struggled to retain. Pain quote is generic Squarespace/Zapier, off-target.

What it does. AI shopping copilots and adaptive product pages embedded into e-commerce stores to lift discovery and conversion.

The public-data read. The monetization line is the alarm: a 110-month payback. The headline SaaS price band is $1-10/mo while CAC runs $244-812 off a $24.37 CPC, so the consumer-priced framing is fundamentally broken (the brief itself says "$2-10/mo will not support expensive acquisition unless you sell B2B"). It competes with Bloomreach, Constructor, Nosto, Coveo, Gorgias and Tidio, established commerce-search incumbents. Budget proof is genuinely strong (10/10): Nosto's 66% consumer-openness stat, the Alibaba field experiment (+3% sales, -12.55% returns), and Shopify's Jan 2026 ChatGPT Instant Checkout onboarding. But demand is LUKEWARM (8% transactional) and funding is 4/10 with category validation Cool. Real business hides in the API/white-label tiers ($12k-250k/yr), not the consumer SaaS pitch.

What it does. Builds the intelligence software layer for autonomous drones.

The public-data read. A bifurcated profile: pain is BURNING (25/30) and monetization scores STRONG (17/20), but demand is LUKEWARM and the intent is the giveaway — 2,230 searches/mo at only 8% transactional, KD 48, which is researchers and hobbyists, not buyers. The competitor wall is the entire defense-autonomy A-list: Palladyne AI, Shield AI, Anduril, Skydio, ModalAI, plus AeroVironment and Quantum Systems — a "10" count that for frontier hardware is the low-confidence default, but here the named players are real and well-armed. The sharpest own-quote is weak as a buying signal: r/explainlikeimfive asking "Surely they can't be using GPS for positions just a few feet apart... how quickly can they respond to wind?" — that's curiosity, not procurement. Monetization reads SaaS up to ~$4,188/yr with a 0.1-month payback on a $42-139 CAC, which is implausibly fast for an autonomy software layer that defense buyers acquire via enterprise contract — the public-data lens is pricing this like self-serve SEO SaaS when the real motion is integrator sales. Funding is COOL (1/10): Skydio's $100M Series C was July 2020 and the category has not produced a software-layer breakout since.

What it does. Expressive, low-latency voice foundation models with one-shot cloning for voice agents.

The public-data read. The wedge is emotion plus latency, and the pain is genuine and specific: 25/30 BURNING with r/LocalLLaMA users saying clones are "missing the emotional part" and r/ElevenLabs calling Resemble "robotic and monotone." Demand is thin but high-intent (170/mo, 100% transactional, leading growth) and KD median is a brutal 72/100, so SEO is a wall. The real problem is who they are standing next to: ElevenLabs (raised $180M, a16z), Cartesia, Resemble, plus OpenAI, Azure Speech, and Amazon Polly as commodity baselines. This is a foundation-model knife fight where the incumbent just out-raised them 10x. CAC $81-270 and a 0.4-month payback look great, but the enterprise-licensing path assumes $150K ARPU on 6-9 month cycles against players with research budgets they cannot match.

What it does. An AI health assistant that helps people with chronic illness track symptoms, spot patterns, and prepare doctor-ready reports.

The public-data read. This is a consumer/patient play (130 searches/mo, only 8% transactional, flat trend) with the weakest funding signal in the group (1.0/10) and the lowest social-pain score (17/30, "CHRONIC" not "BURNING"). Named direct competitors are few but real: Bearable (symptom/mood/med tracking with clinician sharing) and Guava (longitudinal health-record organizing) - both already do "track symptoms, share with doctor." The best on-topic quote is from r/ChronicIllness recommending an existing tool: "I really enjoy PainScale, a head to toe pain tracker that tracks mood & diet" - which is the problem: patients have already found free trackers they like. Budget-proof reads 9/10 but the scraped price is consumer-tier ($6-$78/mo), and chronically ill patients are a notoriously hard-to-monetize, churn-prone segment. Category capital is readable but cautionary: Superpower ($30M series A, AI health risk detection, rel=0.72) and Kiddo ($16M, pediatric chronic conditions, rel=0.83) are plausible adjacents - the pattern of large raises in consumer chronic-care that have not produced a breakout winner is itself a category warning, not a founder gap.

What it does. No-code AI chat that turns plain-language prompts into publishable, browser-playable web games for creators.

The public-data read. The demand floor is the problem: only 80 searches/mo at just 8% transactional intent and KD 24, so this is a content-and-community bet, not a search-capture one, despite the 100k beta-tester claim. Social pain is genuinely BURNING (25/30, 32 mentions across r/gamedev, r/godot, r/NoCodeSaaS, Quora), but it sits against entrenched builders, Rosebud.ai, Replit, Unity, GDevelop, Construct, GameMaker, that already convert the same hobbyists. Monetization is the redeeming pillar ($15-300/mo SaaS) but the math is ugly, CAC $209-698 on a 9.4-month payback against $20.93 CPC, which is brutal for a hobbyist ARPU.

What it does. make products agent-ready

The public-data read. 2,510/mo, 100% transactional, but the competitors are platforms (Microsoft, Salesforce, Kore, Zapier) and "make your product discoverable to agents" is very early. Okta's "secure agentic AI blueprint" is the why-now.

What it does. agent traces & evals

The public-data read. 20/mo, intent LOW, into LangChain, Langfuse, Arize and Datadog, and it overlaps Sazabi and Armature in this same batch. Pain quote ("alternatives to SNMP") is off-target.

What it does. AI operating system for home-care agencies covering participant tracking, staff scheduling, billing, and compliance.

The public-data read. Real budget and regulation tailwinds (HOT funding 7/10; Commure $70M Jun 2026, ExaCare AI $30M), 320 searches/mo at 100% transactional intent, but the competition is labeled TOUGH and entrenched: AlayaCare, AxisCare, WellSky, Axxess, MatrixCare, and Careswitch, the last already branding itself "the AI-powered operating system for home care," i.e. TakeCareOS's exact positioning is taken. The killer is the monetization math: $37/mo price against a $274-$914 CAC yields a 20.1 month payback, which is venture-fatal at SMB price points. The r/nursing "I absolutely cannot stand Axxess... we're moving software companies" quote is the genuine switching wedge.

What it does. Builds welding-automation robots and an open robotics stack for American manufacturing.

The public-data read. This is a hardware play the public-data lens structurally under-rates: monetization is STRONG (16/20) with real budget proof (turnkey welding cells cluster at $50k-300k, multi-robot lines $600k-1.2M+), yet demand reads WARM only because search is a near-dead 25/mo at 8% intent. Pain is CHRONIC, not burning — and the most honest quote, r/Welding's "Production welding is vulnerable to automation, but there are many situations that a robot cannot adapt to. And robots can't replace a welder," is the buyer telling you why automation stalls, not begging for it. The competitor set is the industrial-robotics establishment — Path Robotics, Novarc, FANUC, ABB, KUKA, Yaskawa, Kawasaki, Daihen — with a TOUGH 9.6/24 barrier score that is real, not the soft "10" default. The 0.1-month payback on a $288-960 CAC is absurd for a six-figure capital-equipment sale and should be ignored. The dossier's own founder wedges are the right read: high-mix MIG/TIG job shops, 1-10 cell fab shops, integrators. Funding is COOL (1/10): Path Robotics raised $56M back in May 2021 and AI welding has not broken out since.

What it does. pre-launch agent testing

The public-data read. 40/mo, into RPA giants (Tines, UiPath, ServiceNow, Automation Anywhere) plus overlaps Arga (agent testing) in-batch. Pain quote (config drift) is real ops pain but not agent-specific.

What it does. Embeds AI agents into an SMB's existing tools to automate the operational tasks that block growth, hands-on, done-for-you.

The public-data read. Demand is the highest-volume in the batch (5,190/mo) but rated only LUKEWARM (25/35) because it's just 10% transactional with KD 23, and competition is TOUGH (10.8/24) against the heaviest incumbent wall here: UiPath, Workato, Celonis, Appian, Automation Anywhere, Power Automate, ServiceNow and SAP. The fatal monetization signal: price reads $2-$25/mo while CPC is $59.98 (the highest in the batch) and CAC $600-1,999, producing a 65-month payback, so the file pivots to a $3,000-12,000/mo concierge/services motion, which is consulting, not software. Funding is HOT (8.5/10, $625M incl. Mind Robotics $500M Jun 2026), but that capital validates the category, not Hessian.

What it does. An AI "growth team on autopilot" for DevTools startups, finding customers, testing ideas, and learning across channels.

The public-data read. The demand is a trap: only 80 searches/mo at a punishing KD 59 (the highest in the batch), so the high 83% transactional intent is on a near-empty well. It competes against Clay, Apollo, HubSpot, Salesloft, Drift, Demandbase, and 6sense, all funded and entrenched in growth/RevOps. The "payback 0.1 months" figure is suspect (CPC $5.26 producing CAC $53-175 is implausibly cheap for this buyer) and budget proof is the weakest credible pillar at 3/10 Faint, resting on a single HubSpot stat. The pain quotes are generic SaaS gripes plus HubSpot-is-too-complex threads; the genuinely useful signal is r/SaaS ("a tool that connects ICP to actual acquisition channels could save tons of wasted ad spend"), which is the real wedge.

What it does. Low-cost, mass-produced attack drones.

The public-data read. The demand signals are unusually loud for hardware — 6,600 searches/mo at 100% transactional intent, KD 6, BURNING pain, and Funding HOT (10/10, with Allen Control Systems' $200M and Firestorm's $82M Series B both landing in 2026) — yet monetization is the glaring weak spot at UNCLEAR (13/20). The competitor set is the defense prime tier — AeroVironment, Anduril, Shield AI, General Atomics, Elbit, plus loitering-munition specialist UVision and attritable-jet maker Kratos — a wall where a YC-stage startup competes on price and production scale, not technology. The most relevant quote is r/CredibleDefense: "Western militaries would face significant hurdles in attempting to replicate Ukraine's rapid drone production and innovation, due to slower..." — which names the exact thesis and the exact obstacle (procurement velocity, not engineering). Pricing anchors to ~$35k per one-way drone ($20k-80k Shahed-class), with a CAC of $8-26 and 0.1-month payback that is meaningless here: these are government contracts, not transactions, and the $0.79 CPC / 100% intent profile is search demand for cheap consumer drones bleeding into a defense-procurement product. The real risk is that "mass-produced attack drone" is a manufacturing-and-procurement problem the dossier itself flags as needing a narrower buyer.

What it does. self-running online store

The public-data read. 120/mo, MEDIUM intent, into Shopify itself plus GenStore, RunnerAI and ShopSOS. "AI builds and runs your store" is a crowded 2024-25 thesis. Absurd 511-month payback.

What it does. A compliant AI assistant for therapists that handles clinical notes, treatment plans, and admin work.

The public-data read. Demand is tiny (30 searches/mo, KD 41, negative trend) but 93% transactional, so the handful of searchers are real buyers in a crowded behavioral-health-documentation space. The named competitors are formidable and specific: Upheal and Eleos Health (both therapist-specific AI note tools), Freed (AI scribe), and the incumbent EHRs SimplePractice and TheraNest - meaning Klarify is entering a field where the system-of-record vendors are already shipping AI notes. The most revealing quote is the anti-AI backlash from r/therapists: "I am looking for a way to take notes that has no connection with AI whatsoever. Therapynotes now suggests that I use their AI to write notes" - a real segment of the buyer base is actively hostile to the category. Budget-proof is 9/10 but the scraped price is low ($1-$99/mo) against a buyer (solo/small-practice therapists) that is famously price-sensitive. Category capital is legible and crowded: DeepScribe ($30M series A, rel=0.95) and the very recent Kin Health ($9M seed, 2026, rel=0.9) confirm money is flowing into AI medical/therapy notes - which cuts both ways as validation and as a "you are late" signal.

What it does. investment agents deployed

The public-data read. 5,590/mo, 99% transactional, but barrier-to-entry is the batch's toughest (9.6/24), into brokerage infra (Interactive Brokers, Alpaca, Tradier) and heavy regulation. The JPMorgan AI headline is the tailwind.

What it does. AI agents that automate front-office operations — quoting, order entry, purchasing — for US manufacturers and distributors.

The public-data read. The cleanest software profile in this cohort: monetization STRONG (18/20) with real anchored pricing ($10-2,990/mo from Salesforce and Parsio), a believable 1.4-month payback on a $61-203 CAC, and BURNING pain at 100% transactional intent. The catch is demand is thin (140 searches/mo, LUKEWARM) and it carries a -2 manufacturing build-complexity penalty. Competitors are a CROWDED-BUT-DOABLE 14.4/24: Salesforce Manufacturing Cloud, Plex, Epicor-adjacent Kinetic, ServiceMax, L2L, MasterControl, plus email-parsing player Parsio — incumbents that own the ERP/CRM system of record this product has to integrate around. The on-target quote is r/automation: "I'm looking for recommendations for business process automation tools that hit the sweet spot between ease of use and reliability" — real switching appetite, though several of the dossier's top complaints (HN finance threads, r/gamedev) are off-vertical noise. Funding is WARM (5.5/10), but the named raises — Factory $150M, Hadrian $260M, Nominal $80M — are AI-coding and defense-manufacturing infra, an adjacency stretch, not direct quoting-automation comps.

What it does. Automates government FOIA and public-records request handling, intake, search, PII redaction, and statutory response drafting, for public-sector teams.

The public-data read. Demand is the weakest scored pillar here (15/35, just 40/mo, 8.0% transactional, KD 14), so the file explicitly says "your fastest path to signal is not SEO; it is direct sales," contradicting its own SEO-first 30-day plan. Competitors are the entrenched FOIA stack (NextRequest, FOIAXpress, JustFOIA, GovQA, plus Granicus/Laserfiche), and the buyer is government agencies with 3-6 month deal cycles. Funding is COOL (1/10) with small, old comps (Luminai $16M, City Innovate $12.4M). Budget proof is 9/10 and the per-request economics are real, but the implied 0.2-month payback off a $3.50 CPC is a mirage given public-sector sales cycles.

What it does. AI-powered primary care doctor available 24/7 that explains symptoms, remembers details, and guides care.

The public-data read. Clara has the most real consumer demand in the group on paper - 190 searches/mo at 47% transactional intent, KD 27, across 4 countries - but the trend line is sharply negative (-0.74), the single biggest red flag here, suggesting interest in "AI doctor / symptom checker" framing is cooling even as the dossier optimistically tags demand as "active." The competitor set is crowded and well-capitalized (Doctronic, Curai Health, Transcarent, plus health-system Cedars-Sinai Connect), and the funding records confirm a graveyard-adjacent category: K Health ($50M later, rel 1.0), Ada Health ($90M Series B), Infermedica ($30M), and notably Forward Health ($225M, membership primary care) - that last one is the cautionary CATEGORY signal, a quarter-billion raised into always-on primary care that shut down, telling you the category eats capital. The most honest pain quote actually argues against the product: a Quora physician says "90% of diagnosis is done by how the patient sounds and looks. The other 10% need to come into the office," which is the core skeptic case a symptom-chat tool must overcome. At a scraped $12/mo with 7/10 budget-proof, consumers will pay a little, but the regulatory wall the score ignores is severe: an "AI primary care doctor" that "guides care" brushes against the practice of medicine, state licensure, and liability for missed diagnoses - the legally safe version is a triage tool, and triage is exactly where Ada and Infermedica already saturate.

What it does. AI agents that shadow employees to learn their workflows, then automate them on top of existing systems for SMBs.

The public-data read. Demand is WARM (23/35) with a notable 100% transactional purchase intent and KD 29 on 1,320/mo, the cleanest buying signal of the automation cluster, but social pain is only CHRONIC (16/30, the weakest pain score in the batch) and competition is rated TOUGH against UiPath, Automation Anywhere, Blue Prism, Workato, IBM, Relevance AI, Gumloop and n8n. The deal-breaker is monetization math: price is pinned at $25/mo while CPC is $24.35 and CAC $244-812, producing a 26.4-month payback, you spend a year-plus of revenue to acquire a customer. Funding is COOL (1/10), the largest comp (Workato $200M) is from Nov 2021 and never reset the category.

What it does. Maps a company's workflows and interviews employees to guide tailored enterprise AI adoption.

The public-data read. Demand is LUKEWARM (19/35) on a tiny 80/mo (50% transactional, KD 22) with geo UNKNOWN (0/5 countries with meaningful volume), so there is essentially no organic discovery, yet it lists a PLG/GitHub launch plan that contradicts its own enterprise reality. The "competitors" are Accenture, Deloitte, BCG, IBM, PwC, KPMG and Capgemini, i.e. you are wedging against the Big 4 consultancies, and the monetization paths quote $30k-$250k/yr enterprise licenses with 3-6 month deal cycles and CAC of $18k-28k. Funding is COOL (3.5/10) though the category is Hot ($57M), with Whatfix ($90M, Jun 2021) and FortressIQ ($30M, 2020) as the cautionary comps.

What it does. Brings affordable, mobile, diagnostic-grade MRI imaging directly into clinics.

The public-data read. Demand is effectively absent online - 10 searches/mo at 8% transactional intent (KD unrecorded), the weakest intent in the group - so this is a field-sales and partnerships motion, not a discoverable one. The named competitors are entrenched mobile-imaging operators (RAYUS Radiology, MXR Imaging, DMS Health, Interim Diagnostic Imaging) that already lease OEM-certified Siemens/GE/Philips trailers, so Adialante is entering a logistics-and-capital business, not a software niche. The scraped price note is the most useful signal: consumer self-pay scans run roughly $285-$750 and mobile-MRI equipment leases run $18K-$50K+/mo, which both confirms real money moves here and exposes how capital-intensive the model is. The truest pain quote is from r/AskEngineers - "MRI machines are wildly complex... a modern one costs millions and millions of dollars... they need all kinds of special equipment" - which is exactly the cost wall Adialante claims to beat, and exactly why the funding pillar at 3.5/10 is worrying for a hardware play. The funding records (Subtle Medical, Rad AI) are AI-imaging software companies, not mobile-MRI hardware peers, so true category capital is hard to read from public data. The barrier the 6 signals undercount: a "diagnostic-grade" mobile MRI is an FDA-cleared medical device plus state radiology licensing plus reimbursement coding, a multi-year regulatory path that no content strategy shortens.

What it does. An adaptive AI endurance coach that reshapes cycling, running, and swimming plans around real-life schedule, fatigue, and travel.

The public-data read. 1,030 searches/mo but only 8% transactional and a brutal KD median of 44, sitting against TrainerRoad, TrainingPeaks, Runna, TriDot, Humango and FinalSurge, all of whom already sell "adaptive" coaching. Monetization reads STRONG (1.2-month payback, $11-135/mo, CAC $58-192) but the subscription model's own table shows 28% monthly churn average case, which is a leaky bucket no SEO funnel survives. Social Pain is 21/30 CHRONIC, yet the cited quote, a Strava user whose "ChatGPT adaptive running coach" broke, shows the pain is already being half-solved for free inside ChatGPT.

What it does. agent email infrastructure

The public-data read. 70/mo, MEDIUM intent, into AgentMail, Nylas, Mailgun and Mailtrap. Grammarly acquiring Superhuman signals email consolidation. Great unit economics (CPC $3.50). The r/AI_Agents quote is the exact use case but niche.

What it does. analog circuit copilot

The public-data read. 40/mo, KD 64, urgency very low (2.1), into AI-EDA tools (Flux, SnapMagic, Quilter, JITX). Neuralink hiring analog IC engineers shows the talent is scarce and expensive. Real pain on r/electricalengineering (LLMs cannot design circuits).

What it does. Intelligent prediction market that connects real-world claims, evidence, dependencies, and prices in a single world model.

The public-data read. The sector tag (Banking, Credit & Lending) is clearly wrong - this is a prediction-market / forecasting product, and the data reflects it: only 10 searches/mo, 8% transactional intent, and a 22/35 demand score that the dossier flags as low-velocity. The named competitors are formidable and well-capitalized - Polymarket, Manifold Markets, PredictIt, and Limitless already own the prediction-market category, with Polymarket especially dominant. The most on-topic pain is the r/slatestarcodex user looking for "an alternative to dying Predictit" and asking how reliable Polymarket is - that is real demand, but it is demand for trustworthy liquid markets, not for a "connected world model," which is a research-y wedge users have not asked for. Budget-proof is only 7/10 and intent is 8%, so willingness-to-pay is the weakest in this batch. Category capital is real and heavy here: Polymarket raised $300M and Opinion Labs $20M Series A (both plausible competitors), which signals the category attracts serious money but is consolidating around liquidity leaders, not novel market structures.

What it does. GDPR-compliant, EU-data-residency text-to-speech across 40+ languages for mid-market B2B.

The public-data read. 28,370 searches/mo at 94.8% intent looks huge, but that is generic TTS volume the company will fight ElevenLabs, Cartesia, Deepgram, WellSaid Labs and Resemble for on KD-49 terms, and the wedge (GDPR) is a slice of it. The damning data point: Cartesia already announced GDPR compliance (cited in the file's own budget proof), so the single differentiator is being copied by a better-funded incumbent in real time. Funding is 1/10 COOL with the flagship ElevenLabs round dated Jun 2023 ($19M). Social Pain is the weakest in this batch at 16/30, Neutral, and the quotes are generic TTS-shopping ("what's the best text-to-speech AI tool," r/3CX). Payback is fast (0.8 months) but the model is increasingly commoditized.

What it does. Makes simple, networked, driverless RF test equipment.

The public-data read. A weak demand-and-pain core propped up by hardware budget proof. Pain is only CHRONIC (17/30) at Neutral intensity, demand is LUKEWARM on a near-empty 40 searches/mo at 8% intent, and the competitor set is the test-and-measurement oligopoly — Rohde & Schwarz, Tektronix, Keysight, National Instruments, Anritsu, VIAVI, Yokogawa, Cobham — a genuinely TOUGH 9.6/24 with decades of installed base. The top complaints aren't even on-product: r/embedded "what scope are people using these days?" and r/ElectroBOOM "good oscilloscope for my uncle" are general-purpose-instrument shopping, not demand for driverless RF test. The 0.1-month payback on a $30-99 CAC is the public-data lens misreading a capital-equipment category where used high-end analyzers run to $185k. Funding is WARM (6.5/10) but the named raises — Darkhive $30M, WaiV $7.5M, Paladin $17M — are drone companies, not RF-test comps, so the wedge has no funded validation. The dossier's wedges (drone/robotics OEM pre-cert RF workflows) are the only credible path.

What it does. Develops hyper-efficient cooling to maximize data-center compute. (Sector tag is auto-generated and wrong — this is data-center thermal infra, not robotics.)

The public-data read. Rides the strongest macro tailwind in the cohort — AI data-center heat — but the public-data signals are middling: pain CHRONIC (21/30), demand LUKEWARM (370/mo, 8% intent, KD 24), monetization WORKABLE (15/20). Crucially, the payback here is honest at 6.3 months on an $85-284 CAC — the longest in this group and a refreshing contrast to the implausible 0.1-month numbers elsewhere, which signals the lens actually found real enterprise-sales pricing ($10k-90k/rack, projects over $10M). The competitor wall is the thermal establishment — Vertiv, Schneider Electric, CoolIT, Submer, LiquidStack, Boyd, Airedale/Modine, Johnson Controls — TOUGH and capital-intensive. The genuinely on-vertical quotes are real demand-side confusion: r/datacenter's "liquid cooling" alternatives thread and r/ArtificialInteligence asking "why do data centres consume so much water" — though several top complaints (r/aviation aircooled-vs-watercooled engines) are off-topic. Funding is COOL (3.5/10): JetCool $17M (2023, Bosch/In-Q-Tel), Accelsius $24M, Corintis $25M — modest Series A's, no breakout, meaning capital is testing the category but no winner has emerged.

What it does. Offers global traders compliant leveraged trading of top US stocks at up to 20x leverage.

The public-data read. Demand data is effectively absent (0 searches/mo, KD None) despite a high 53% transactional intent reading on whatever sliver exists, and the $135/mo scraped price suggests a subscription wrapper over brokerage. The named competitors are heavyweight and licensed: Interactive Brokers, IG and CMC Markets already offer leveraged global-equity and CFD access in regulated markets. The most on-topic pain is the r/CryptoExchange complaint that "it's frustrating how restrictive the US is" on leveraged/futures access - which is real demand for offshore leverage but also a giant flashing regulatory warning, because 20x leverage on US stocks for "global traders" is precisely the CFD/offshore-margin product that is banned for US persons and tightly licensed everywhere else. The other quotes (Indie Hackers API reliability, r/PersonalFinanceCanada free platforms) are off-topic noise. Funding is WARM but the records are noise (Rogo is generative-AI-for-finance, NewRetirement and PINA are planning tools, none are leverage-trading competitors), so capital and competition are hard to read from public data. The entire premise rests on threading securities/derivatives licensing across jurisdictions, the exact thing the 6-signal score never priced.

What it does. Builds passive aerial sensing mesh networks for defense and surveillance.

The public-data read. Monetization scores STRONG (19/20) and Funding is HOT (7.0/10) on the back of defense capital — but both are category-level mirages here. Pain is only CHRONIC (17/30) at Neutral intensity, demand is a near-dead 30 searches/mo at 8% intent, and the competitor set is the air-defense and counter-UAS elite: Anduril, Dedrone by Axon, MARSS, L3Harris, Thales, Shield AI, AeroVironment, Skydio. The monetization "anchor" is contaminated — the public pricing it found ($7.99-24.99/mo software, $29.99-399.99 hardware) is the consumer Arlo home-security brand, not a defense sensing mesh, so the 19/20 STRONG score and 0.8-month payback on a $35-117 CAC are a name-collision artifact and should be discarded. The on-vertical quotes are thin: r/LessCredibleDefence's "Anduril gets benefit of the doubt compared to L3 Harris" is industry chatter about the competitors, not a buyer in pain. Funding HOT is real but it's everyone else's — Anduril's $2.5B and CHAOS Industries' $275M (2025) — a category signal that capital is flooding defense sensing, with no passive-mesh breakout among it.

What it does. Builds programmable DNA-based therapeutics designed to find and eliminate cancer.

The public-data read. This is a therapeutics biotech wearing a software-style dossier, and the framework barely fits it - lowest LRS in the group (42.1) with the lowest urgency (2.2/10), because there is no near-term buyer, no SEO motion (20 searches/mo, KD 15), and no product to sell for years. The named competitors are real oncology biotechs (Geneos Therapeutics for DNA-based personalized immunotherapy, BioNTech, Cybrexa, Imanis), confirming a legitimate but brutally hard scientific category rather than a market with switchable buyers. The sourced pain quotes are essentially patient/public hope and curiosity - r/Futurology on CRISPR selectively destroying cancer cells, r/explainlikeimfive worrying "it seems like a very difficult thing to test, modifying DNA and hoping there are no bad side effects" - which is sentiment, not demand, and the "who pays" monetization fields (patients/insurers per therapeutic) are speculative given nothing is approved. Funding looks plausibly on-category: FoRx Therapeutics ($50M Series A + $10M seed, DNA-repair-stress cancer therapeutics, rel 0.95) and TwoStep/DNA Therapeutics are real-ish peers, but the modest seed sizes and a 3.5/10 funding pillar tell you this is early, capital-hungry science where a single $50M round barely starts the work. The barrier the 6 signals fundamentally cannot capture: this is a multi-year, multi-hundred-million-dollar FDA path through preclinical, IND, and Phase 1-3 trials with binary clinical risk - everything about the demand/SEO/monetization scoring is the wrong lens for a preclinical drug program.

What it does. Builds satellite-based air traffic control connecting every aircraft and drone to a global network.

The public-data read. The most capital- and regulation-intensive idea in the cohort, and the signals reflect it: Funding scores NONE (0/10) — the lens found exactly one relevant raise (Frontier Aerospace $10M, 2023) — which for space ATC is a flashing warning that the category is either nascent or dominated by incumbents who don't raise venture. Pain is CHRONIC (17/30) Neutral, demand LUKEWARM (530/mo, 8% intent). The competitor set is the aerospace/ATM establishment plus the one real space-ADS-B player: Aireon, Skykraft, L3Harris, Thales, Viasat Iris, Honeywell, Northrop, Saab. The genuine on-vertical quote is real and structural — r/flying's "we have to do something about ATC staffing" and the Quora thread on "the difficulties of upgrading the FAA's aging networks" — burning systemic pain, but pain felt by a government regulator, not a self-serve buyer. The 0.4-month payback on a $35-117 CAC is meaningless against estimated $500k-5M+ annual enterprise contracts; this is an RFP-and-constellation business the public-data lens cannot price.

What it does. AI that builds and then continuously optimizes SMB websites on autopilot, an always-on growth layer rather than a static builder.

The public-data read. Volume looks healthy at 46,030 searches/mo, but only 8% is transactional at KD 40, so the headline demand is mostly informational against Wix, Framer, Hostinger, Lovable, Durable, and Unbounce, all of whom already own "AI website builder." Social pain is only CHRONIC (20/30) and the quoted threads are tellingly low-stakes: r/Entrepreneur side-hustlers asking what to charge for Wix sites, and users praising B12 and Hostinger, this is a switching-cost-zero, commoditized job. Payback is the bright spot at 4.8 months with CAC $187-623, but the real signal is the funding graveyard. The "continuous optimization" wedge is the only non-commodity angle.

What it does. Creates clinically validated, personalized patient discharge-education videos in 75+ languages within minutes.

The public-data read. Framewise has the weakest profile in the group (LRS 40.9, lowest demand pillar at 16/35) - 45 searches/mo, KD 11, 44% transactional - so demand is low but the keyword is easy to rank, which fits the SEO-led, partnerships-first plan if hospitals can be reached at all. The competitor data is noisy: the dossier lists Framewise itself as competitor #1, then Aidoc (radiology AI) and Augmedics (AR surgical navigation), neither of which is a patient-education peer, so the similar-ideas extraction misfired and the real competitive set is hidden. The funding records are more informative than the competitor list: Mytonomy ($32M, "cloud patient education video platform," rel 0.9) is a direct, well-funded incumbent doing exactly this, which is the key CATEGORY signal - patient-education video is an established, funded niche, not greenfield, and Framewise must beat Mytonomy on speed and language coverage. None of the sourced pain quotes are on-topic (an ebike chainring thread, a copyright question, a bilingual-upbringing debate) - the noise filter failed here, so there is no credible buyer-pain evidence in this dossier, which is itself a yellow flag. At a scraped $200/mo and 9/10 budget-proof the unit pricing looks SMB-friendly, but the barrier the score ignores is real: "clinically validated" discharge education touches patient-safety liability and health-system procurement, and hospitals buy through slow committees, so the partnerships-first plan is correct but the sales cycle is the true constraint.

What it does. Builds swarms of autonomous subsea drones to monitor and protect critical underwater infrastructure.

The public-data read. A timely thesis — subsea cable/pipeline protection — with the weakest demand surface in the group: 20 searches/mo, though notably MEDIUM intent (33.3% transactional, KD 0), and pain only CHRONIC (20/30) Neutral. Monetization is WORKABLE (14/20), the lowest-confidence here, with the lens admitting pricing is mostly RFP-based ($7k commercial subsea robots up to tens of thousands) and a 0.1-month payback on a $38-125 CAC that is fiction for defense-grade subsea hardware. The competitor set is the naval-defense and subsea-robotics elite: Thales, Saab, Sonardyne, Kongsberg, L3Harris, Anduril, HII, Bluefin Robotics — a TOUGH wall with shipbuilding-scale relationships. None of the top quotes is a buyer: r/NuclearPower on underwater SMRs, r/ecology on drones for invasive species, r/submarines on a navy career — these are tangential curiosity, not procurement pain. Funding is COOL (3.5/10): Vatn Systems $13M (Lockheed Ventures, 2024), Swarmer $15M — small defense-adjacent seeds, no breakout.

What it does. Turns consulting-heavy enterprise software implementation into a weeks-long self-serve rollout platform.

The public-data read. Only 60 searches/mo (the thinnest top of funnel in this batch) at 93.3% intent, and it lists Accenture, Deloitte, IBM Consulting, ServiceNow, Salesforce, Microsoft, Moveworks and Kore.ai as competitors, i.e. it is selling against the Big Four consultancies whose entire business model is the slow implementation Lab0 wants to kill. Barrier is 9.6/24 TOUGH and channel is sales-led. The monetization contradiction is glaring: a $10-220/mo SaaS band against a 9.9-month payback, CAC $421-1,402, and a real business model (API/white-label) at $25k-250k/yr with 90-120 day deal cycles. Social Pain is 21/30 with strong, on-target ERP-pain quotes (r/ERP "people dread ERP implementation").

What it does. Text/SMS-based frontline helpdesk that answers worker questions about shifts, SOPs, and HR policy from company documents.

The public-data read. This one is demand-starved: 20 searches/mo, 44.4% transactional, so there is no SEO channel to win despite the file insisting on a GitHub/Dev.to PLG motion that contradicts a frontline-ops buyer. Competition is brutal and adjacent (ServiceNow, Aisera, Rezolve.ai, Zendesk, Intercom, plus Axonify for frontline enablement). Pricing of $132-$200/mo with a $33-$111 CAC and 1.4 month payback looks cheap, but the file's own economics show a $2,000 average CAC and 18% churn in the SaaS-sub case. The honest signal from r/Rag, "very easy to get to about 75% accuracy, getting to 90%+ is very, very difficult," is the real product risk for an SMS bot answering safety/HR questions.

What it does. AI maintenance assistant for industrial teams that speeds troubleshooting, boosts uptime, and preserves expert knowledge.

The public-data read. The clearest case in the cohort of strong economics undercut by zero discoverable demand: monetization is STRONG (19/20) with real anchored CMMS pricing ($8-355/mo from MaintainX, Fiix, Brightly) and a credible 2.0-month payback on a $35-117 CAC — but demand is COLD (16/35) on literally 0 searches/mo, the worst in the group, dragging the LRS to last. Pain is CHRONIC (21/30) Neutral. The competitor set is CROWDED-BUT-DOABLE (14.4/24): MaintainX, Fiix, Brightly, IBM Maximo, LLumin, plus sensor-AI players Augury and Tractian and analytics player Uptake — and critically, MaintainX already ships AI copiloting inside its mobile CMMS, putting an incumbent directly on Pairio's wedge. The best quote is a live buying moment: r/maintenance, "We're looking for a CMMS for our plant. We've looked at MaintainX, Zoidii, and Limble... I want to hear what [others use]" — real shopping, but shopping for a CMMS, not a standalone AI assistant. Funding is WARM (5.5/10) but the named raises (Skild AI $1.4B, Mind Robotics $500M, Landing AI $57M) are robotics/CV foundation plays, not maintenance-software comps.

What it does. Platform for building leveraged parlays across prediction markets on anything.

The public-data read. The sector tag (Wealthtech & Personal Finance) is wrong; this is a prediction-market / betting product. The demand signal is mixed and a little suspicious: 440 searches/mo at a flat-out 100% transactional intent (KD 44), which reads more like a generic "parlay" gambling query than dedicated demand for cross-market parlays, and budget-proof is a weak 3/10 with a $1-150/mo price band - the lowest budget-proof in the group. The named competitors are on point: Polymarket (the underlying market), Novig (peer-to-peer sports prediction trading) and Robinhood (now pushing event-based trading to the mainstream). There is essentially no usable pain quote - the only one captured is a Stack Overflow Python error ("ValueError: X has 1 features, but SVC is expecting 3") that is pure noise, so the social-pain pillar has no real on-topic voice here, a meaningful gap. Funding is COOL and the records are off-category wealth-planning tools (Facet, Dezerv, Personal Capital, HyperNorm AI), not parlay/prediction competitors, so capital is unreadable. The dominant unscored reality: "leveraged parlays on anything" is a gambling product by another name, and parlays plus leverage is exactly the structure that draws CFTC, state gaming, and responsible-gambling scrutiny.

What it does. single-file local VMs

The public-data read. 0 search (COLD), into Firecracker (free, open-source), UTM and Parallels. A developer-elegance product with a weak payment signal.

What it does. Builds humanoid robots for elder care.

The public-data read. This is deep-atoms eldercare hardware, and the public-data lens treats it harshly — search is just 10/mo and urgency is LOW (3.5/10), but that's exactly what you'd expect for a humanoid-robot company whose buyers are facility operators, not Googlers. Pain is real but only CHRONIC 17/30, and the most honest signal is that the loudest sentiment is against the thesis: a Quora respondent argues "robots should never be used in nursing homes where elder care is being administered... elderly people need the human touch." The competitor wall is serious and well-funded — Intuition Robotics (ElliQ), Labrador Systems, Apptronik (Apollo), SoftBank Robotics, UBTech — and Apptronik just raised a $350M Series A (Feb 2025), so capital in humanoids is not the constraint, distribution and a real job are. Monetization is the suspicious part: the report's own comps put care robots at $20,000–$250,000+ enterprise ACVs, yet it prints a $9–32 CAC and 0.1-month payback, which is the default placeholder and implausible for a robot you have to physically deploy and service. The weakest signal is urgency; the strongest is that eldercare budgets are demonstrably real. Treat the competitor count of 10 and the sub-month payback as low-confidence artifacts of an atoms business the public lens can't see.

What it does. An accessible 3D ultrasound device aiming to become a "3D camera for the body."

The public-data read. This is the only hardware/regulated-device bet in the group and it shows the weakest profile - low demand (40 searches/mo, 8% transactional, KD 63 the hardest in the batch) and merely "WORKABLE" monetization (15/20). Named competitors are mostly the wrong category: Styku, Fit3D, and BodySpec are fitness/wellness body-composition scanners, while SimonMed Longevity and TrueScan are whole-body MRI/CT screening services - none is a true accessible-3D-ultrasound peer, so the competitive set is fuzzy. The most on-topic pain quote is brutal and about the incumbent consumer device: r/withings "The Body Scan was hands down the worst consumer electronics purchase I've ever made. Expensive, slow, and inaccurate. Mine is back in its box" - plus an Indie Hackers note that "a mere 5-degree tilt results in a 2-3cm error," flagging that 3D body capture accuracy is genuinely hard. Budget-proof is 9/10 with a wide scraped band ($87-$3899/mo), consistent with a device + software model. Category capital is partly readable: Sonair ($7M seed + $6M series A, 3D ultrasonic sensing, rel=0.95) and Q Bio ($27M, full-body scanner, rel=0.9) are plausible adjacents - and the fact that well-funded full-body-imaging plays exist without a clear consumer winner is a category-difficulty signal, not a founder question.

What it does. Builds open infrastructure and an operating system for counter-drone defense interoperability.

The public-data read. This is a frontier-defense play where a low public score is almost guaranteed and almost meaningless: 40 searches/mo at 8% transactional intent reflects that NATO program offices and defense primes don't shop on Google, not that demand is absent. The signals that do matter are strong — monetization is 18/20 STRONG and pain is CHRONIC 21/30 with clear payment intent, and the most relevant complaint is the builder-truth from Indie Hackers: "It's easy to call an API. It's far harder to build real infrastructure than many founders realise... Founders want to ship so rush to deliver." That cuts both ways for an "operating system for interoperability." The competitor set is the entire defense establishment — Anduril, Leonardo DRS, Raytheon, Lockheed Martin, CACI — plus narrower players Picogrid, D-Fend, and Dedrone, which is exactly the wall a connective-infrastructure layer has to either ride or get crushed against. The reported $38–125 CAC and 1.4-month payback are unrealistic against contracts the report itself pegs at $30K–$2B with government RFP cycles; the real CAC is a multi-quarter capture motion, not a paid click. Weakest signal is urgency (4.5/10 MEDIUM); the bet rests on procurement timing nobody can rush.

What it does. Deploys robotic stations across cities that clean, charge, and inspect autonomous vehicles to keep them on the road.

The public-data read. Aseon scores low on the public lens for a structural reason — 0/mo search volume — but its non-demand signals are the strongest in this group: monetization 20/20 STRONG, funding 10/10 HOT, and CHRONIC 21/30 pain with clear payment. The funding signal is genuinely category-defining: Waymo's $16B raise (Feb 2026), Waabi's $750M, Wayve's $1.3B, Shield AI's $2B — the AV fleets that would buy depot-in-a-box stations are flush. The most on-point pain is a Hacker News commenter describing AV charging centers that "currently only have security guards there. The logistics of having cleaning [stations]" being unsolved — which is precisely Aseon's wedge, observed in the wild. But the competitor list is a tell that the map is low-confidence: it names Waymo, Zoox, Cruise, Pony.ai — the *fleet operators themselves*, who are potential customers, not competitors, and lists Aseon as its own competitor. So competition 12/24 is noisier than it looks. The $15–50 CAC with 0.1-month payback is the implausible-default again for a business that pours concrete and installs robotic hardware city by city. Weakest real signal is urgency (4.6/10); the existential question is build-vs-buy — do flush AV operators in-house this?

What it does. Turns video calls into real-time, photorealistic AI-generated experiences via an embeddable/API product.

The public-data read. The only Cold rating here, and the budget proof tells you why: 4/10 Faint, with essentially one generic Google Cloud citation backing paid demand. It faces HeyGen, D-ID, Synthesia, Tavus, Uneeq and Pickle, all established AI-avatar players, on a KD-69 keyword ("how to improve video call quality"). The economics are punishing: Avg CPC of $48.75 drives CAC to $488-1,625, and the easiest path to revenue (white-label) needs $10k-100k/yr enterprise licenses with a long sales cycle, not the PLG motion the plan recommends. Demand is 24/35 WARM at 96.7% intent, but on only 640 searches/mo with Faint budget proof, this looks like a tech demo chasing a use case.

What it does. AI agents run a consumer brand's marketing, sourcing, operations, and support end-to-end as a single operating layer.

The public-data read. This is among the weakest signals in the batch and the data shows why: 0/mo direct searches (53.3% transactional), no demand surface beyond Google, so there is zero pull and validation has to come from cold pilots. The pain is real (25/30 BURNING, 39 mentions across r/MachineLearning, r/marketing, Hacker News, Indie Hackers) but the loudest quotes are anti-AI disillusionment ("the greatest swindle of all time," "0 paying customers") rather than demand for an agent-run brand. They are walking into a fully-staffed category: Zowie, Gorgias, Octane AI, Triple Whale, Pencil, Daydream all ship today with marquee logos (Allbirds, Sephora, Decathlon). The monetization math is the tell: $35-117 CAC looks fine until you see the stated 95-month payback and a $1/mo floor price signal, while the SaaS model assumes $4,500-6,500 CAC against $1,500 ARPU.

What it does. Ultra-low-latency teleoperation software that lets companies remotely operate and scale robot fleets from anywhere.

The public-data read. Avea is the rare entry here that's actually *software*, so its low LRS is harder to wave away — but 0/mo search still reflects an emerging B2B category, not dead demand, and intent is the highest in this group at 53.3% transactional. Competition is the most crowded of the cohort at 13.2/24 (CROWDED BUT DOABLE), against a genuinely deep teleop field: Formant, Tangent Robotics, InOrbit, teleop, Extend Robotics, plus Phantom Auto's prior $95M raise. Pain is only CHRONIC 17/30 at Neutral intensity, and tellingly the "top complaints" are off-target — Quora threads about software-vs-mechatronics careers and "robot manipulator control problems," with the closest real signal being an r/PLC integrator on "recurring, compounding problems... estimation misses" on large robot projects. That's adjacent, not a buyer screaming for teleop. Funding is COOL (3.5/10) — Phantom Auto raised $95M and didn't break out teleop as a standalone category, which is a category caution flag, not a founder one. The $35–117 CAC / 0.1-month payback is more plausible here than for the hardware entries but still optimistic for enterprise robotics sales. Weakest signal is funding-as-category-momentum.

What it does. AI wallet that automatically picks the best payment card to use at checkout to maximize rewards.

The public-data read. The Crypto & DeFi tag is a misfire; the product and every direct competitor (Fina, MaxRewards, CardPointers, Curve, Bilt) are mainstream credit-card-rewards optimizers, not DeFi. Demand is weak and declining: 70 searches/mo, a downward trend, and a 39.0 cold LRS, with the dossier's own constraint flagging low search volume requiring heavy content/community work. The competitive set is the real problem: MaxRewards and CardPointers already do exactly "which card to use at checkout," and Curve already ships a physical card that switches the funding source after purchase, so Uno is entering a solved consumer category with established apps. The social-pain quotes are mostly off-topic noise (a SaaS-business-model thread, a payment-processor testing thread, a finance-class rant), and the closest relevant one, r/personalfinance on not saving cards on file, is about security habits, not reward optimization, so the pain signal is genuinely thin. The scraped price band ($1-$250,000/mo) is nonsensical and unreliable. Category capital is hard to read: the records (AI Pay With Crypto, MORPHO DeFi lending, SignalPlus crypto trading) are crypto-noise from the mistaken tag and are not real comps for a card-rewards app, so public funding tells us nothing useful about this category. The unscored layer is the quiet killer for consumer card apps: monetizing usually means affiliate/issuer referral economics or card-linked-offer data, which raises consumer-data-privacy and card-network-rules questions, and the affiliate model has thin, fragile margins.

What it does. Short-form social AI games that friends create, remix, and share, a "TikTok for UGC games" consumer play.

The public-data read. This is among the coldest files in the batch (WEAK SIGNAL) and the demand is almost nonexistent, 40 searches/mo, so this lives or dies on virality, not search. The saving grace is the only genuinely consumer-scale economics here: CAC $27-90, a 1.7-month payback, and benchmarked ARPU of $8.50-14 against Roblox, Discord, Fortnite, Rec Room. But social pain (21/30) is muddied, the quoted "complaints" are a grab-bag of PS4 boot errors and "I have too many friends to play with," not a sharp wedge, and the r/sandbox quote is the real threat: "market getting filled with billions of AI slop." Funding is HOT (8.5/10, Status AI $17M/a16z, Born $15M/Bessemer), which here reads as category froth more than validation.

What it does. real-world AI datasets

The public-data read. 0 search, into data-labeling giants (Scale AI, Appen, iMerit) for physical-AI data. The robotics-data-shortage narrative is real (r/robotics: "too little real-world data"). A crypto/contributor-network model adds quality and consent friction.

What it does. autonomous company operations

The public-data read. 50/mo but barrier-to-entry 8.4/24 (among the most copyable, i.e., no moat), and "AI runs your whole company" is a maximalist claim against Microsoft, Salesforce and UiPath. Doability is the issue.

What it does. physical-AI deployment layer

The public-data read. 0 search, barrier-to-entry 9.6/24, into the silicon/edge giants (NVIDIA, Intel, Edge Impulse, Hailo). CES physical-AI momentum is the narrative. Very early, no pricing data.

What it does. self-healing desktop agents

The public-data read. 0 search, barrier-to-entry 9.6/24, into RPA incumbents (UiPath, Microsoft, Automation Anywhere, Blue Prism). r/rpa shows fierce UiPath loyalty, and NVIDIA shipping proactive consumer-PC agents is a direct threat.

What it does. Generates custom home blueprints in seconds with instant PDF and CAD export, aimed at SMB builders and homeowners.

The public-data read. This is a WEAK SIGNAL (Cold) for a reason: only 40/mo direct searches at 8.0% transactional, so there is effectively no demand surface to capture, even though social pain scores BURNING (25/30, 36 mentions). The named field, Swapp, Graphisoft Archicad, Snaptrude, Planner5d, RoomSketcher, Chief Architect, is mature and SEO-led, and budget proof came back 0/10 (no validated spend). Drafted itself raised $16M (May 2026, Buckley Ventures, YC, Ben Silbermann) while comparable Maket raised only $3.4M back in 2023 and never broke out, which is a category caution flag.

What it does. Search engine for prediction markets that compares real-time Kalshi vs Polymarket odds and surfaces arbitrage.

The public-data read. The sector tag (Wealthtech & Personal Finance) is wrong; this is a prediction-market / betting tool. This is the coldest project in the group - Demand 10/35, only 10 searches/mo at 8% transactional intent, negative trend - so almost nobody is searching for an "odds comparison engine" by name. The named competitors are directly on point: Polymarket itself, OddsJam (already does cross-book arbitrage for sports), and SportsDataIO (the odds-feed API), meaning the arbitrage-comparison playbook already exists in the sports-betting world. The strongest pain quote is genuinely informative - the r/PredictionMarkets note that "Kalshi dominates sports volume (~85%+), Polymarket dominates politics/crypto... if you only use one platform you're missing half the picture" - which validates the cross-market thesis even if search demand does not. Budget-proof is only 7/10 and the price band ($30-3795/mo) is wide and uncertain. Funding is COOL and the records are off-category noise (Myne, HyperNorm AI, WealthReach, Seeds, RockFi are all wealth-advisor tools, not prediction-market infra), so category capital is unreadable here. The regulatory wrinkle: a pure comparison/search tool is low-risk, but the moment "surfaces arbitrage" becomes order routing it inherits prediction-market and state-by-state gambling licensing exposure.

What it does. AI-native financial terminal for healthcare that aggregates live data from 125+ sources for banks and hedge funds.

The public-data read. The sector tag (Fintech & Payments) is misleading; Soria is a vertical financial-data terminal for healthcare investors, closer to AlphaSense/Koyfin than to anything in payments. The demand signal is effectively absent: 0 searches/mo and KD None, which is why the LRS is the coldest in the batch at 37.3; this is a partnerships-and-outbound motion, not a discoverable category. The named competitors (Koyfin, AlphaSense, BamSEC) are general financial-research platforms, so Soria's bet is that healthcare-specific aggregation beats horizontal tools, but the dossier shows no funded healthcare-finance-terminal comp at all ("no funding records"), which cuts both ways: either a genuine white space or a market too small for anyone to have funded. The best on-topic pain quote is the Quora "inexpensive or free alternative to EIKON and Bloomberg terminal" thread, confirming the perennial appetite to escape terminal pricing, though the other quotes are about healthcare data engineering/integration, a different (harder) problem than market intelligence. Budget-proof is 9/10 but the scraped price is only $100/mo, which is wildly under terminal-economics for a bank/hedge-fund buyer and suggests the pricing is unsettled. With no public category capital, competition and capital are genuinely hard to read from public data, so the honest stance is uncertainty, not a competitive verdict.

What it does. Builds AI scientists that discover new materials for the semiconductor industry, compressing lab-to-fab timelines.

The public-data read. Mislabeled "AI & Automation," matforge is really deep-tech materials discovery, and the public lens predictably under-rates it: 0/mo search and Neutral-intensity pain understate a field where buyers are fab R&D teams, not search users. The signals that count are healthy — monetization 20/20 STRONG, funding 7/10 HOT, and intent 66.7% transactional, the highest in this group. Funding is a real category tailwind: CuspAI's $100M Series A and Periodic Labs' $200M (a16z, both 2025) show AI-for-materials is being capitalized hard right now. The competitor field is the most crowded of the cohort at 15.6/24 — Citrine Informatics (mature enterprise), Mat3ra, Materials Zone, Kebotix, QDX — meaning materials-informatics is established turf, not greenfield. The honest weak spots: pain is only 20/30 at Neutral, the top quote is a generic "Why is it so hard to manufacture semiconductors?" (Quora) rather than a buyer in acute pain, and the pricing anchor is literally $0–$0/mo with a null payback — there's no real WTP data, which is the single biggest gap. The weakest signal is pain intensity; the bet is that fab budgets convert curiosity into contracts.

What it does. A real-time AI scribe that drafts pathology reports by voice and routes findings into any LIS or IMS.

The public-data read. The coldest entry in the batch (LRS 36.5, "WEAK SIGNAL") with effectively no measurable demand - 0 searches/mo, KD None, funding 0/10 - so the entire thesis rests on a narrow specialty (pathology) that simply does not generate keyword volume. The named competitors are the heavily-funded ambient-scribe field: Suki AI, DeepScribe, Nabla, Ambience Healthcare, and Commure - all general clinical scribes, which means Voquill's only real differentiation is the pathology/LIS-routing niche the generalists ignore. The most on-topic quote is the buyer's true decision criterion from r/healthcare: "The integration with your specific EMR matters more than raw accuracy - a 98% accurate tool that requires manual copy-pasting is worse than a 95" - which validates the "routes into any LIS/IMS" wedge as the thing that actually matters. Budget-proof is 9/10 with a low scraped price ($7-$70/mo), and 47% transactional intent on the tiny query base hints the few who search are serious. Category capital is barely readable: the only sourced record is Proscia ($50M, digital pathology platform, rel=0.97) - a plausible pathology-adjacent whose scale signals the category has real money but also an entrenched platform Voquill must integrate with or around.

What it does. AI audit-intelligence engine that automates SOX ITGC and BPC testing, pulling evidence and producing reviewer-ready workpapers.

The public-data read. Demand is the killer here: 0 searches/mo, KD None, 47% transactional intent, and a 12.0/35 demand score that the dossier itself flags as the top constraint. The competitor wall is real and entrenched - AuditBoard, Workiva, Caseware, DataSnipper, and Trullion all own the evidence-extraction and workpaper workflow Arden wants to automate. The sharpest pain signal is an r/InternalAudit buyer literally comparing incumbents ("I have implemented workiva and AB... Workiva is also cheaper than AB. I hate AB"), which tells you the budget exists but the switching decision is already a two-horse incumbent race, not a greenfield. Budget-proof scores 9/10 and pain mentions hit 38, so the wallet is there; the question is discovery, since a SEO-led GTM into 0 search volume means nobody is looking for this category by name. The scraped $1/mo price note is clearly partial/placeholder, funding is 0/10, and the two "category capital" records (Antithesis, Evidence) are software-testing and dev-analytics companies, not audit competitors, so category capital is effectively unreadable from public data here.

What it does. AI agents that source Indonesian manufacturers by scanning factories, verifying certifications, and prepping quotes within 48 hours.

The public-data read. Saudara is a vertical sourcing-automation play whose low LRS comes mostly from 0/mo search — but unlike the frontier-hardware entries, this is a software/marketplace category where zero search is a more genuine demand warning, which the report flags by saying "you will need outbound proof, not passive demand." The real pain is solid (CHRONIC 20/30, Clear payment) and on-target: an r/startups founder "looking for a domestic manufacturer to create a large volume of custom designs... I do not know where to start," and r/manufacturing noting "communication and lead times can be a challenge... you'll need to vet suppliers more carefully." Competition is CROWDED BUT DOABLE (12/24) against incumbents that are mostly *human* services — Sourcing Indonesia, Cosmo Sourcing, Dragon Sourcing — plus marketplaces Alibaba, MFG, Global Sources; the wedge is automating the agency. Monetization is WORKABLE with a believable 2.1-month payback and $30–99 CAC — the most credible economics in this group precisely because it's a software business, not atoms. The funding badge (HOT 10/10) is noise here: the records are Databricks, Cyera, Nscale — generic a16z/Sequoia mega-rounds with nothing to do with sourcing. Weakest signal is search demand; the question is whether buyers trust an agent over a human sourcing agent for a high-trust transaction.

What it does. Designs and builds ultra-compact nuclear reactors for power generation.

The public-data read. This is the clearest case in the cohort of the public lens punishing atoms: it's a nuclear-reactor company mislabeled "AI & Automation," carrying a −4 build-complexity penalty, and it still has the *highest* search demand here at 1,150/mo. That said, intent is LOW (8% transactional, KD 48) and pain is the weakest of all nine at MILD 13/30 — the top "complaints" are genuinely neutral curiosity ("Why do nuclear power plants need to be retired after ~50 years?" / "nuclear reactors can't explode... incredibly safe," both Quora/Reddit), which is people learning about nuclear, not buyers in pain. Funding is HOT (8.5/10) and real: Oklo, X-energy ($700M Series D, Nov 2025), Last Energy ($100M), Radiant ($300M), Aalo Atomics — microreactors are deeply capitalized and the competitive field is formidable. The monetization line is absurd for the category — a $400/mo price scraped from GE's site and a 0.3-month payback for a *nuclear reactor* — pure artifact; real comps are utility/industrial power deals measured in years and hundreds of millions of capex. Weakest signal is pain; the honest read is that this is a capital-and-regulatory marathon the demand lens simply cannot measure, where the right question is licensing and offtake, not search.

What it does. A space-logistics company building low-cost, reusable heat shields for high-frequency cargo return from orbit.

The public-data read. Dispatch is the deepest-frontier entry and the public lens is essentially blind to it — 0/mo search, no CPC, urgency LOW (3.2/10), no pricing or CAC data at all — which says far more about a pre-revenue space-hardware company than about its prospects. The signals that exist are mixed-positive: CHRONIC 17/30 pain and CROWDED BUT DOABLE competition (13.2/24). The genuinely on-target pain is technical and well-sourced — Quora threads asking "what issues do they face with the heatshield tiles on Starship" and "how can we design a reusable spacecraft that doesn't need heat-shield tiles" — real engineering pain, though it's discussion, not procurement. The competitor field is serious and adjacent: Varda Space ($187M Series C), Inversion Space ($50M, a16z/Gigafund), Space Forge, Outpost, Canopy Aerospace, Stoke, and SpaceX itself — most of these own the *whole* reentry vehicle, so Dispatch's reusable-TPS-as-a-layer thesis must prove it isn't just a component the integrators build themselves. Monetization is the weakest signal — literally N/A price, null CAC, null payback — meaning there is no WTP evidence whatsoever; the entire bet is on reuse economics nobody has yet validated. The competitor count of 10 and the absent unit economics are both low-confidence artifacts of a category with almost no public surface.

What it does. real-world tasks marketplace

The public-data read. 0 search, demand 11/35 (lowest in batch), into marketplaces with massive liquidity moats (TaskRabbit, Upwork, Fiverr, Thumbtack). "Agents hire humans" is a clever inversion but unproven.

What it does. Builds bird-like robotic drones for surveillance.

The public-data read. Lowest LRS in the group, and demand is the bluntest reason — 0/mo search and a COLD demand rating (18/35), the only COLD in this cohort — but for a stealth-surveillance hardware product the buyers are security integrators and infrastructure teams who never search "robotic bird drone," so cold public demand badly understates a real but invisible market. Pain is actually CHRONIC 21/30 at Frustrated intensity with clear payment, and the most relevant signal is honestly a *limitation* of the concept: a Quora respondent notes "small drones might be part of a surveillance effort, but they lack the 'long stare' needed to surveil a subject" — i.e., the very thing biomimetic drones must overcome. The competitor field is real and well-funded: The Drone Bird Company (production biomimetic hardware), Shield AI, Skydio, Percepto, BRINC, Saildrone — and funding is HOT (10/10) with Firestorm $82M, Advanced Navigation $111.9M, Fortem $25M, all 2025–26. So capital in autonomous/defense drones is abundant; the question is why bird-shaped specifically. Monetization is WORKABLE with a 1.9-month payback and $38–125 CAC, but the only concrete price anchor is a $145 consumer toy bird drone — not a real enterprise signal, so the unit economics are unanchored and the competitor count of 10 is the low-confidence default. Weakest signal is demand; the bet is that discretion is worth a hardware premium to one specific buyer.